PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 21833458-0 2011 Dermatan sulfate reduces monocyte chemoattractant protein 1 and TGF-beta production, as well as macrophage recruitment and myofibroblast accumulation in mice with unilateral ureteral obstruction. Dermatan Sulfate 0-16 chemokine (C-C motif) ligand 2 Mus musculus 25-59 21833458-8 2011 DS treatment significantly (P < 0.05) reduced the content of collagen (stained area ~700 microm(2)), MCP-1 (stained area ~160 microm(2)) and TGF-beta (stained area ~5% of total area), in addition to myofibroblast (stained area ~190 microm(2)) and macrophage (number of cells ~32) accumulation in the obstructed kidney. Dermatan Sulfate 0-2 chemokine (C-C motif) ligand 2 Mus musculus 104-109 17395211-5 2007 It was found that administration of tacrine, rivastigmine and donepezil in mice significantly attenuated the LPS induced increased levels of IL-2 along with the significant reduction of AChE activity predominantly in salt soluble (SS) fraction as compared to the detergent soluble (DS) fraction in a dose dependent manner. Donepezil 62-71 interleukin 2 Mus musculus 141-145 17395211-5 2007 It was found that administration of tacrine, rivastigmine and donepezil in mice significantly attenuated the LPS induced increased levels of IL-2 along with the significant reduction of AChE activity predominantly in salt soluble (SS) fraction as compared to the detergent soluble (DS) fraction in a dose dependent manner. Donepezil 62-71 acetylcholinesterase Mus musculus 186-190 17005066-1 2007 BACKGROUND: There is general consensus regarding the benefit of acetylcholinesterase inhibitors (e.g. donepezil) in Alzheimer"s disease (AD). Donepezil 102-111 acetylcholinesterase (Cartwright blood group) Homo sapiens 64-84 17362438-2 2007 The authors describe a patient with features of typical MH who was successfully treated with donepezil, a cholinesterase inhibitor, as a combination therapy and who has not shown any subsequent cognitive decline for approximately 5 years. Donepezil 93-102 butyrylcholinesterase Homo sapiens 106-120 17469693-2 2007 Cholinesterase inhibitors may be of benefit in DLB and PDD, as suggested by placebo-controlled clinical trials of rivastigmine and donepezil. Donepezil 131-140 butyrylcholinesterase Homo sapiens 0-14 17207478-16 2007 We also examined the effects of antimuscarinic drugs on learning enhanced by the cholinesterase inhibitor donepezil at a dose of 0.1 mg/kg i.v. Donepezil 106-115 butyrylcholinesterase Rattus norvegicus 81-95 16525416-3 2007 Oral administration of the novel nitrate, GT1061 (4-methyl-5-(2-nitroxyethyl) thiazole HCl), and the acetylcholinesterase inhibitor, donepezil, reversed the cognitive deficits in both memory tasks in a dose-dependent manner. Donepezil 133-142 acetylcholinesterase Rattus norvegicus 101-121 18449461-5 2007 We therefore asked whether donepezil (a long-acting acetylcholinesterase inhibitor used in the treatment of Alzheimer"s disease) can antagonize morphine-induced respiratory depression. Donepezil 27-36 ACE-1 Oryctolagus cuniculus 52-72 17194818-1 2007 OBJECTIVE: The objective of this study was to evaluate donepezil, an acetylcholinesterase inhibitor, in the treatment of frontotemporal dementia (FTD). Donepezil 55-64 acetylcholinesterase (Cartwright blood group) Homo sapiens 69-89 17272964-1 2007 The objective of this study was to examine the effects of adjunctive treatment with the acetylcholinesterase inhibitor, donepezil, on cognitive deficits and psychopathology in schizophrenic patients treated with the antipsychotic, ziprasidone. Donepezil 120-129 acetylcholinesterase (Cartwright blood group) Homo sapiens 88-108 18044073-7 2007 Rivastigmine (Exelon, Novartis Basel-Switzerland) is a slowly reversible inhibitor of acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE), while donepezil (Aricept, Pfizer, New York, USA) and galantamine (Reminyl, Janssen, New Jersey, USA) show no functional inhibition of BuChE, and are considered AChE-selective, rapidly-reversible inhibitors. Donepezil 155-164 acetylcholinesterase (Cartwright blood group) Homo sapiens 309-313 17192712-1 2007 BACKGROUND: We examined attention-enhancing effects of the cholinesterase inhibitor donepezil in Dementia with Lewy bodies (DLB) and Parkinson"s disease with dementia (PDD) by means of open label study. Donepezil 84-93 butyrylcholinesterase Homo sapiens 59-73 17057756-0 2006 The anti-amnesic and neuroprotective effects of donepezil against amyloid beta25-35 peptide-induced toxicity in mice involve an interaction with the sigma1 receptor. Donepezil 48-57 sigma non-opioid intracellular receptor 1 Mus musculus 149-164 17057756-1 2006 BACKGROUND AND PURPOSE: The acetylcholinesterase inhibitor, donepezil, is also a high affinity sigma(1) receptor agonist. Donepezil 60-69 acetylcholinesterase Mus musculus 28-48 17057756-1 2006 BACKGROUND AND PURPOSE: The acetylcholinesterase inhibitor, donepezil, is also a high affinity sigma(1) receptor agonist. Donepezil 60-69 sigma non-opioid intracellular receptor 1 Mus musculus 95-112 17033976-9 2006 CONCLUSION: This study showed significative differences in the global treatment persistence among the considered drug-cholinesterase inhibitors, showing higher persistence resulting in patients treated with donepezil compared to those who received rivastigmine, galantamine or memantine. Donepezil 207-216 butyrylcholinesterase Homo sapiens 118-132 16797936-0 2006 Acetylcholinesterase inhibitor donepezil in the treatment of cognitive deficit in schizophrenia. Donepezil 31-40 acetylcholinesterase (Cartwright blood group) Homo sapiens 0-20 16820527-5 2006 Pain induced by Donepezil undermined the efficacy of the drug, resulted in increased carer stress and worsening cognition not reversed by the change of medication to another cholinesterase inhibitor. Donepezil 16-25 butyrylcholinesterase Homo sapiens 174-188 16868793-1 2006 OBJECTIVES: To evaluate long-term changes in acetylcholinesterase (AChE) activity in CSF and blood following donepezil treatment in relation to the concentration of donepezil and cognition in AD patients. Donepezil 109-118 acetylcholinesterase (Cartwright blood group) Homo sapiens 67-71 16868793-1 2006 OBJECTIVES: To evaluate long-term changes in acetylcholinesterase (AChE) activity in CSF and blood following donepezil treatment in relation to the concentration of donepezil and cognition in AD patients. Donepezil 165-174 acetylcholinesterase (Cartwright blood group) Homo sapiens 67-71 17060346-3 2006 There is type 1a evidence for cholinesterase inhibitors (donepezil, rivastigmine and galantamine) for mild to moderate Alzheimer"s disease; memantine for moderate to severe Alzheimer"s disease; and for the use of bright light therapy and aromatherapy. Donepezil 57-66 butyrylcholinesterase Homo sapiens 30-44 17047484-0 2006 Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer"s disease. Donepezil 76-85 butyrylcholinesterase Homo sapiens 10-31 17047484-8 2006 Wild-type BuChE carriers showed significantly greater responses to rivastigmine than to donepezil on the SIB, ADCS-ADL, GDS and NPI. Donepezil 88-97 butyrylcholinesterase Homo sapiens 10-15 16905267-8 2006 donepezil hydrochloride (DON), a centrally acting acetylcholinesterase inhibitor, were investigated in conscious sham-operated (SO) and cerebral infarcted (CI) rats. Donepezil 0-23 acetylcholinesterase Rattus norvegicus 50-70 16905267-8 2006 donepezil hydrochloride (DON), a centrally acting acetylcholinesterase inhibitor, were investigated in conscious sham-operated (SO) and cerebral infarcted (CI) rats. Donepezil 25-28 acetylcholinesterase Rattus norvegicus 50-70 16889901-8 2006 We also found that donepezil enhanced, and scopolamine suppressed, the expression level of phosphorylated cAMP response element binding protein (CREB), which is related to cell survival, in the DG. Donepezil 19-28 cAMP responsive element binding protein 1 Rattus norvegicus 106-143 16889901-8 2006 We also found that donepezil enhanced, and scopolamine suppressed, the expression level of phosphorylated cAMP response element binding protein (CREB), which is related to cell survival, in the DG. Donepezil 19-28 cAMP responsive element binding protein 1 Rattus norvegicus 145-149 16889901-9 2006 These results indicate that donepezil enhances and scopolamine suppresses the survival of newborn cells in the DG via CREB signaling without affecting neural progenitor cell proliferation and the neuronal differentiation. Donepezil 28-37 cAMP responsive element binding protein 1 Rattus norvegicus 118-122 17032609-2 2006 Three cholinesterase inhibitors (donepezil, rivastigmin og galantamin) are approved mild to moderate Alzheimer"s disease and one partial NMDA receptor antagonist (memantin) with the indication moderate to severe Alzheimer"s disease. Donepezil 33-42 butyrylcholinesterase Homo sapiens 6-20 17124641-3 2006 RESULTS: The present study indicates that in the elderly persons, donepezil, an acetylcholinesterase inhibitor also exerts a marked effect on REM sleep parameters: REM density was increased whereas REM latency was reduced, thus, confirming the findings of our pilot study described earlier. Donepezil 66-75 acetylcholinesterase (Cartwright blood group) Homo sapiens 80-100 17015988-4 2006 Donepezil Hydrochloride (I) can be determined in the presence of up to 70% of its oxidative degradate (II) using (D(0)), 80% using (D(1)) and 90% using (D(2)). Donepezil 0-23 leiomodin 1 Homo sapiens 131-136 17015988-4 2006 Donepezil Hydrochloride (I) can be determined in the presence of up to 70% of its oxidative degradate (II) using (D(0)), 80% using (D(1)) and 90% using (D(2)). Donepezil 0-23 iodothyronine deiodinase 2 Homo sapiens 152-157 17016152-10 2006 Donepezil treatment did not improve P50 sensory gating in AD patients but decreased P50 amplitude. Donepezil 0-9 activating signal cointegrator 1 complex subunit 1 Homo sapiens 84-87 17016152-12 2006 Donepezil does not affect P50 sensory gating but reduces P50 amplitude. Donepezil 0-9 activating signal cointegrator 1 complex subunit 1 Homo sapiens 57-60 17016152-13 2006 Donepezil may induce P50 amplitude reduction by means of enhanced dopamine release. Donepezil 0-9 activating signal cointegrator 1 complex subunit 1 Homo sapiens 21-24 16413803-6 2006 In this work we proposed molecular hybrids of tacrine with donepezil (fusion of these structures), in order to suggest new proposals of AChE inhibitors for future treatment of AD. Donepezil 59-68 acetylcholinesterase (Cartwright blood group) Homo sapiens 136-140 16478570-3 2006 Donepezil inhibits cholinesterase, thus enhancing cholinergic neurotransmission. Donepezil 0-9 butyrylcholinesterase Homo sapiens 19-33 17415417-0 2006 Interaction of acetylcholinesterase inhibitor donepezil with ionic channels of the neuronal membrane. Donepezil 46-55 acetylcholinesterase (Cartwright blood group) Homo sapiens 15-35 16856114-12 2006 In the first study the 13-item ADAS-Cog showed benefit associated with 10 mg/day donepezil compared with placebo at 24 weeks (MD 1.90, 95% CI 0.51 to 3.29, p=0.007), but four other measures of cognitive function did not. Donepezil 81-90 alkylglycerone phosphate synthase Homo sapiens 31-35 16845507-0 2006 Impact of the CYP2D6 polymorphism on steady-state plasma concentrations and clinical outcome of donepezil in Alzheimer"s disease patients. Donepezil 96-105 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 14-20 16845507-1 2006 OBJECTIVE: The aims of this study were to evaluate the impact of the CYP2D6 polymorphism on both the steady-state plasma concentrations (Cp) and the clinical outcome of donepezil, a selective acetylcholinesterase inhibitor used in the treatment of Alzheimer"s disease (AD). Donepezil 169-178 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 69-75 16845507-10 2006 CONCLUSIONS: Our preliminary data suggest that the CYP2D6 polymorphism influences both donepezil metabolism and therapeutic outcome and that a knowledge of a patient"s CYP2D6 genotype together with donepezil concentration measurements might be useful in the context of improving the clinical efficacy of donepezil therapy. Donepezil 87-96 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 51-57 16880719-1 2006 Donepezil, galanthamine, and tacrine are therapeutic acetylcholinesterase (AChE) inhibitors used for the treatment of Alzheimer"s disease. Donepezil 0-9 acetylcholinesterase Rattus norvegicus 53-73 16880719-1 2006 Donepezil, galanthamine, and tacrine are therapeutic acetylcholinesterase (AChE) inhibitors used for the treatment of Alzheimer"s disease. Donepezil 0-9 acetylcholinesterase Rattus norvegicus 75-79 16880719-7 2006 On the other hand, the neuroprotective effects of donepezil and galanthamine, but not of tacrine, against neurotoxicity induced by moderate glutamate treatment were mediated through the phosphatidylinositol 3-kinase-Akt pathway. Donepezil 50-59 AKT serine/threonine kinase 1 Rattus norvegicus 216-219 16901641-4 2006 A single oral dose (3mg) of donepezil, an acetylcholinesterase inhibitor that is commonly used to treat Alzheimer"s disease (AD), improved SAI in DAI patients with wide individual variations that ranged from an increase of 77-18% of test size. Donepezil 28-37 acetylcholinesterase (Cartwright blood group) Homo sapiens 42-62 16762377-1 2006 We show here that donepezil, galanathamine and tacrine, therapeutic acetylcholinesterase inhibitors currently being used for treatment of Alzheimer"s disease, protect neuronal cells in a time- and concentration-dependent manner from glutamate neurotoxicity that involves apoptosis. Donepezil 18-27 acetylcholinesterase (Cartwright blood group) Homo sapiens 68-88 16762377-5 2006 Inhibitors for a non-receptor type tyrosine kinase, Fyn, and janus-activated kinase 2, suppressed the neuroprotective effect of donepezil and galanthamine, but not that of tacrine. Donepezil 128-137 FYN proto-oncogene, Src family tyrosine kinase Homo sapiens 52-55 16762377-7 2006 The phosphorylation of Akt, an effector of PI3K, and the expression level of Bcl-2, an anti-apoptotic protein, increased with donepezil and galanthamine treatment, but not with tacrine treatment. Donepezil 126-135 AKT serine/threonine kinase 1 Homo sapiens 23-26 16762377-7 2006 The phosphorylation of Akt, an effector of PI3K, and the expression level of Bcl-2, an anti-apoptotic protein, increased with donepezil and galanthamine treatment, but not with tacrine treatment. Donepezil 126-135 BCL2 apoptosis regulator Homo sapiens 77-82 16762377-8 2006 These results suggest that donepezil and galanthamine prevent glutamate neurotoxicity through alpha4- and alpha7-nAChRs, followed by the PI3K-Akt pathway, and that tacrine protects neuronal cells through a different pathway. Donepezil 27-36 AKT serine/threonine kinase 1 Homo sapiens 142-145 16600641-1 2006 Acetylcholinesterase inhibitors (AChEI) such as donepezil act in mild Alzheimer"s disease (AD) by increasing cholinergic tone. Donepezil 48-57 acetylcholinesterase (Cartwright blood group) Homo sapiens 0-20 16990077-10 2006 In a 3-year, randomized, double-blind, placebo-controlled study in 769 patients with a-MCI, treatment with the cholinesterase inhibitor donepezil was associated with a significantly lower rate of progression to AD compared with placebo during the first 12 months of treatment (hazard ratio=0.42; 95% CI, 0.24-0.76; P=0.004) but not at later time points. Donepezil 136-145 butyrylcholinesterase Homo sapiens 111-125 16989488-2 2006 The cholinesterase inhibitors (ChEIs) donepezil, rivastigmine and galantamine have a central role in the treatment of Alzheimer"s disease in the mild to moderate stages. Donepezil 38-47 butyrylcholinesterase Homo sapiens 4-18 16551835-1 2006 Donepezil is a potent acetylcholinesterase inhibitor that also interacts with the sigma1 receptor, an intracellular neuromodulatory protein. Donepezil 0-9 sigma non-opioid intracellular receptor 1 Mus musculus 82-97 16816014-2 2006 Preliminary studies suggest that cholinesterase inhibitors, including donepezil, may reduce behavioral disturbances in patients with Alzheimer disease (AD). Donepezil 70-79 butyrylcholinesterase Homo sapiens 33-47 16551835-5 2006 Preadministration of the sigma1 receptor antagonist N-[2-(3,4-dichlorophenyl)ethyl]-N-methyl-2-(dimethylamino)ethylamine (BD1047) blocked only the igmesine and donepezil effects. Donepezil 160-169 sigma non-opioid intracellular receptor 1 Mus musculus 25-40 16551835-10 2006 These results showed that donepezil is a potent antiamnesic and neuroprotective compound against the neurodegeneration induced by excitotoxic insult, and its pharmacological actions as both an acetylcholinesterase inhibitor and sigma1 receptor agonist contribute to its marked efficacy. Donepezil 26-35 sigma non-opioid intracellular receptor 1 Mus musculus 228-243 16764099-1 2006 (1) Cholinesterase inhibitors such as donepezil, galantamine and rivastigmine, are not very effective in slowing the cognitive decline associated with Alzheimer"s disease. Donepezil 38-47 butyrylcholinesterase Homo sapiens 4-18 16717181-2 2006 Systemic nicotine and an acetylcholinesterase inhibitor, donepezil, attenuated the reinstatement of MAP-seeking behavior by means of the activation of nicotinic acetylcholinergic receptors, but not muscarinic acetylcholinergic receptors, in the nucleus accumbens core, prelimbic cortex, amygdala, and hippocampus. Donepezil 57-66 acetylcholinesterase Rattus norvegicus 25-45 16533671-1 2006 Cholinesterase inhibitors including donepezil, rivastigmine, and galantamine and the N-methyl-D-aspartate (NMDA) antagonist, memantine are the medications currently approved for the treatment of Alzheimer"s disease (AD). Donepezil 36-45 butyrylcholinesterase Homo sapiens 0-14 16397090-9 2006 The donepezil and igmesine effects were blocked by preadministration of the sigma(1) receptor antagonist N-[2-(3,4-dichlorophenyl)ethyl]-N-methyl-2-(dimethylamino) ethylamine (BD1047) and an in vivo antisense probe treatment. Donepezil 4-13 sigma non-opioid intracellular receptor 1 Mus musculus 76-93 16397090-13 2006 Therefore, donepezil behaved as an effective sigma(1) receptor agonist on these behavioral responses, and an interaction of the drug with the sigma(1) receptor must be considered in its pharmacological actions. Donepezil 11-20 sigma non-opioid intracellular receptor 1 Mus musculus 45-62 16199109-1 2006 A chronic treatment with a cholinesterase inhibitor, donepezil (0.085 mg/kg/h for 30 days) increases significantly the number and amplitude of growth hormone (GH) pulses in 3- and 24-month-old rats without modifying nadir GH values. Donepezil 53-62 gonadotropin releasing hormone receptor Rattus norvegicus 143-157 16772755-4 2006 Results show that cholinesterase inhibitors such as donepezil protect cortical neurons against glutamate neurotoxicity via alpha4beta2 and alpha7 nicotinic acetylcholine receptors at least partly by inhibiting the process of apoptosis. Donepezil 52-61 butyrylcholinesterase Homo sapiens 18-32 16833044-5 2006 Recently, two studies have been published about the positive role of cholinesterase inhibitor donepezil on stroke recovery. Donepezil 94-103 butyrylcholinesterase Homo sapiens 69-83 16611014-7 2006 Donepezil (100 microM) and Rivastigmine (100 microM) both reduced the vasoconstrictor effect of Abeta peptides, and significantly restored the endothelial vascular response to acetylcholine. Donepezil 0-9 amyloid beta precursor protein Rattus norvegicus 96-101 16611014-11 2006 We raise the notion that Donepezil and Rivastigmine mediate these vascular modulatory effects via an action on Abeta-mediated vasoconstrictor mechanisms rather than an independent action on endothelial or smooth muscle cell mediated responses. Donepezil 25-34 amyloid beta precursor protein Rattus norvegicus 111-116 16581404-1 2006 BACKGROUND: The cholinesterase inhibitor donepezil is used to treat mild-to-moderate Alzheimer"s disease. Donepezil 41-50 butyrylcholinesterase Homo sapiens 16-30 16397090-5 2006 Of potential therapeutic relevance, donepezil binds to the sigma(1) receptor with high affinity (K(i) = 14.6 nM) in an in vitro preparation (Neurosci Lett 260:5-8, 1999). Donepezil 36-45 sigma non-opioid intracellular receptor 1 Mus musculus 59-76 16481671-2 2006 Because work in dementia documents improvement in executive function deficits with the acetylcholinesterase inhibitor donepezil, the authors reason that similar benefits could be obtained in PDD. Donepezil 118-127 acetylcholinesterase (Cartwright blood group) Homo sapiens 87-107 16445950-7 2006 Expression and production of MCP-1 and IL-4 were significantly increased in AD subjects under therapy with the AChEI Donepezil, compared to the same AD patients at time of enrollment (P < 0.001). Donepezil 117-126 C-C motif chemokine ligand 2 Homo sapiens 29-34 16445950-7 2006 Expression and production of MCP-1 and IL-4 were significantly increased in AD subjects under therapy with the AChEI Donepezil, compared to the same AD patients at time of enrollment (P < 0.001). Donepezil 117-126 interleukin 4 Homo sapiens 39-43 16445950-8 2006 Our data suggest another possible explanation for the ability of Donepezil [diethyl(3,5-di-ter-butyl-4-hydroxybenzyl)phosphonate] to delay the progression of AD; in fact, Donepezil may modulate MCP-1 and IL-4 production, which may reflect a general shift towards type Th0/Th2 cytokines which could be protective in AD disease. Donepezil 65-74 C-C motif chemokine ligand 2 Homo sapiens 194-199 16445950-8 2006 Our data suggest another possible explanation for the ability of Donepezil [diethyl(3,5-di-ter-butyl-4-hydroxybenzyl)phosphonate] to delay the progression of AD; in fact, Donepezil may modulate MCP-1 and IL-4 production, which may reflect a general shift towards type Th0/Th2 cytokines which could be protective in AD disease. Donepezil 65-74 interleukin 4 Homo sapiens 204-208 16445950-8 2006 Our data suggest another possible explanation for the ability of Donepezil [diethyl(3,5-di-ter-butyl-4-hydroxybenzyl)phosphonate] to delay the progression of AD; in fact, Donepezil may modulate MCP-1 and IL-4 production, which may reflect a general shift towards type Th0/Th2 cytokines which could be protective in AD disease. Donepezil 171-180 C-C motif chemokine ligand 2 Homo sapiens 194-199 16445950-8 2006 Our data suggest another possible explanation for the ability of Donepezil [diethyl(3,5-di-ter-butyl-4-hydroxybenzyl)phosphonate] to delay the progression of AD; in fact, Donepezil may modulate MCP-1 and IL-4 production, which may reflect a general shift towards type Th0/Th2 cytokines which could be protective in AD disease. Donepezil 171-180 interleukin 4 Homo sapiens 204-208 16549835-1 2006 PURPOSE: A prospective, open-label phase II study was conducted to determine whether donepezil, a US Food and Drug Administration-approved reversible acetylcholinesterase inhibitor used to treat mild to moderate Alzheimer"s type dementia, improved cognitive functioning, mood, and quality of life (QOL) in irradiated brain tumor patients. Donepezil 85-94 acetylcholinesterase (Cartwright blood group) Homo sapiens 150-170 16549835-10 2006 CONCLUSION: Cognitive functioning, mood, and health-related QOL were significantly improved following a 24-week course of the acetylcholinesterase inhibitor donepezil. Donepezil 157-166 acetylcholinesterase (Cartwright blood group) Homo sapiens 126-146 16449754-1 2006 Cholinesterase inhibitor (ChEI) medications (ie, donepezil, rivastigmine, and galantamine) have been useful in slowing the progression of the mild to moderate stages of Alzheimer"s disease (AD). Donepezil 49-58 butyrylcholinesterase Homo sapiens 0-14 16503777-1 2006 Donepezil, a selective acetylcholinesterase (AChE) inhibitor, has been shown to reduce intraocular pressure (IOP) in ocular normotensive rabbit eyes. Donepezil 0-9 acetylcholinesterase (Cartwright blood group) Homo sapiens 23-43 16503777-1 2006 Donepezil, a selective acetylcholinesterase (AChE) inhibitor, has been shown to reduce intraocular pressure (IOP) in ocular normotensive rabbit eyes. Donepezil 0-9 acetylcholinesterase (Cartwright blood group) Homo sapiens 45-49 16503777-8 2006 These findings show that donepezil, and, possibly, other selective AChE inhibitors, can potentially be used to treat glaucoma. Donepezil 25-34 acetylcholinesterase (Cartwright blood group) Homo sapiens 67-71 16601937-0 2006 P300 auditory event-related potentials and neuropsychological study during donepezil treatment in vascular dementia. Donepezil 75-84 E1A binding protein p300 Homo sapiens 0-4 16601937-3 2006 For one month we studied the effects of donepezil, an acetylcholinesterase inhibitor (5 mg daily), on the cognitive system using P300 auditory event-related potentials (P300) and neuropsychological tests in 10 patients affected by probable VaD according to the NINDS-AIREN criteria. Donepezil 40-49 acetylcholinesterase (Cartwright blood group) Homo sapiens 54-74 16601937-4 2006 Our data showed a significant improvement of neuropsychological items and P300 latency after one month of donepezil treatment. Donepezil 106-115 E1A binding protein p300 Homo sapiens 74-78 16601937-5 2006 In conclusion both P300 and neuropsychological tests are indicated in patients with VaD to confirm the efficacy of donepezil treatment during follow-up. Donepezil 115-124 E1A binding protein p300 Homo sapiens 19-23 17168714-14 2006 Some studies evaluated cholinesterase inhibition in vivo with PET (Positron Emission Tomography) with higher reductions for rivastigmine than for donepezil in several cortical areas. Donepezil 146-155 butyrylcholinesterase Homo sapiens 23-37 16437532-1 2006 BACKGROUND: Since the introduction of the first cholinesterase inhibitor (ChEI) in 1997, most clinicians and probably most patients would consider the cholinergic drugs, donepezil, galantamine and rivastigmine, to be the first line pharmacotherapy for mild to moderate Alzheimer"s disease.The drugs have slightly different pharmacological properties, but they all work by inhibiting the breakdown of acetylcholine, an important neurotransmitter associated with memory, by blocking the enzyme acetylcholinesterase. Donepezil 170-179 butyrylcholinesterase Homo sapiens 48-62 16437532-10 2006 MAIN RESULTS: The results of 13 randomized, double blind, placebo controlled trials demonstrate that treatment for periods of 6 months and one year, with donepezil, galantamine or rivastigmine at the recommended dose for people with mild, moderate or severe dementia due to Alzheimer"s disease produced improvements in cognitive function, on average -2.7 points (95%CI -3.0 to -2.3), in the midrange of the 70 point ADAS-Cog Scale. Donepezil 154-163 alkylglycerone phosphate synthase Homo sapiens 416-420 16720956-2 2006 The cholinesterase inhibitors donepezil, rivastigmine, and galantamine have demonstrated efficacy in improving cognition and global status and to a lesser extent, behavioral abnormalities relative to placebo in patients with mild-to-moderate Alzheimer"s disease. Donepezil 30-39 butyrylcholinesterase Homo sapiens 4-18 16323253-9 2006 Treatment with donepezil, rivastigmine or galantamine resulted in significantly better cognitive performance using the ADAS-cog scale when compared with placebo. Donepezil 15-24 alkylglycerone phosphate synthase Homo sapiens 119-123 16323253-14 2006 CONCLUSIONS: The cholinesterase inhibitors donepezil, rivastigmine, and galantamine can delay cognitive impairment in patients with mild to moderately-severe AD for at least 6 months duration. Donepezil 43-52 butyrylcholinesterase Homo sapiens 17-31 16466174-6 2006 Immunohistochemical test showed that the number of positive stained neuron of PSD-95 and Shank-1 in hippocampus CA1 zone in the model group was significantly different to those in the normal group (P < 0.01), while in the GETO group those indexes were insignificantly different to those in the donepezil group and the normal group (P > 0.05), but showed a significant difference when compared with those in the model group (P < 0.05). Donepezil 294-303 discs large MAGUK scaffold protein 4 Rattus norvegicus 78-84 16466174-6 2006 Immunohistochemical test showed that the number of positive stained neuron of PSD-95 and Shank-1 in hippocampus CA1 zone in the model group was significantly different to those in the normal group (P < 0.01), while in the GETO group those indexes were insignificantly different to those in the donepezil group and the normal group (P > 0.05), but showed a significant difference when compared with those in the model group (P < 0.05). Donepezil 294-303 SH3 and multiple ankyrin repeat domains 1 Rattus norvegicus 89-96 16466174-6 2006 Immunohistochemical test showed that the number of positive stained neuron of PSD-95 and Shank-1 in hippocampus CA1 zone in the model group was significantly different to those in the normal group (P < 0.01), while in the GETO group those indexes were insignificantly different to those in the donepezil group and the normal group (P > 0.05), but showed a significant difference when compared with those in the model group (P < 0.05). Donepezil 294-303 carbonic anhydrase 1 Rattus norvegicus 112-115 16154269-1 2005 Donepezil, a potent acetylcholinesterase (AChE) inhibitor and memantine, an N-methyl-d-aspartate (NMDA) receptor antagonist, have been used for the treatment of Alzheimer"s disease (AD), and both of them have been shown to have neuroprotective action against glutamate excitotoxicity. Donepezil 0-9 acetylcholinesterase Rattus norvegicus 20-40 16154269-1 2005 Donepezil, a potent acetylcholinesterase (AChE) inhibitor and memantine, an N-methyl-d-aspartate (NMDA) receptor antagonist, have been used for the treatment of Alzheimer"s disease (AD), and both of them have been shown to have neuroprotective action against glutamate excitotoxicity. Donepezil 0-9 acetylcholinesterase Rattus norvegicus 42-46 16230018-0 2005 Donepezil-tacrine hybrid related derivatives as new dual binding site inhibitors of AChE. Donepezil 0-9 acetylcholinesterase (Cartwright blood group) Homo sapiens 84-88 16144975-11 2005 Such neuroprotection seemed to be linked to alpha7 nicotinic receptors and the PI3K-Akt pathway in the case of galantamine and donepezil but not for rivastigmine. Donepezil 127-136 AKT serine/threonine kinase 1 Homo sapiens 84-87 22500154-2 2006 It is a specific and reversible inhibitor of acetylcholinesterase (AChE); by increasing levels of available acetylcholine, donepezil may compensate for the loss of functioning cholinergic brain cells. Donepezil 123-132 acetylcholinesterase (Cartwright blood group) Homo sapiens 67-71 16137794-0 2005 Synthesis and biological evaluation as AChE inhibitors of new indanones and thiaindanones related to donepezil. Donepezil 101-110 acetylcholinesterase (Cartwright blood group) Homo sapiens 39-43 16137794-1 2005 Sixty-four new indanones and thiaindanones related to donepezil were synthesized and evaluated in vitro as potential AChE inhibitors. Donepezil 54-63 acetylcholinesterase (Cartwright blood group) Homo sapiens 117-121 16144975-1 2005 Donepezil, rivastigmine, and galantamine are three drugs with acetylcholinesterase (AChE)-inhibiting activity that are currently being used to treat patients suffering from Alzheimer"s disease. Donepezil 0-9 acetylcholinesterase (Cartwright blood group) Homo sapiens 62-82 16144975-1 2005 Donepezil, rivastigmine, and galantamine are three drugs with acetylcholinesterase (AChE)-inhibiting activity that are currently being used to treat patients suffering from Alzheimer"s disease. Donepezil 0-9 acetylcholinesterase (Cartwright blood group) Homo sapiens 84-88 16144975-8 2005 The phosphoinositide 3-kinase (PI3K)-Akt blocker 2-(4-morpholinyl)-8-phenyl-1(4H)-benzopyran-4-one hydrochloride (LY294002) reversed the protective effects of galantamine, donepezil, and nicotine but not that of rivastigmine. Donepezil 172-181 AKT serine/threonine kinase 1 Homo sapiens 37-40 16286445-4 2005 Patients were scanned again after a 10-week open treatment with the cholinesterase-inhibitor donepezil. Donepezil 93-102 butyrylcholinesterase Homo sapiens 68-82 16286546-2 2005 OBJECTIVE: To determine whether measures of hippocampal volume and shape predict the response to donepezil in patients with DAT. Donepezil 97-106 solute carrier family 6 member 3 Homo sapiens 124-127 16286546-6 2005 PATIENTS: Thirty-seven patients with very mild or mild DAT received donepezil therapy for up to 4 weeks before magnetic resonance imaging and for 24 to 96 weeks after magnetic resonance imaging. Donepezil 68-77 solute carrier family 6 member 3 Homo sapiens 55-58 16286546-10 2005 CONCLUSIONS: Measures of hippocampal volume and surface variation can be used to predict the response of patients with DAT to the acetylcholinesterase inhibitor donepezil. Donepezil 161-170 solute carrier family 6 member 3 Homo sapiens 119-122 16362770-1 2005 Donepezil is a selective inhibitor of acetylcholinesterase (AChE) clinically used for treating Alzheimer"s disease. Donepezil 0-9 acetylcholinesterase Rattus norvegicus 60-64 16362770-6 2005 Preliminary results of AChE activity in human blood showed 60-97% and 43-89% of pre-exposed level after one and three days of donepezil administration (5 mg daily), respectively. Donepezil 126-135 acetylcholinesterase (Cartwright blood group) Homo sapiens 23-27 15920507-0 2005 Estimation of plasma IC50 of donepezil hydrochloride for brain acetylcholinesterase inhibition in monkey using N-[11C]methylpiperidin-4-yl acetate ([11C]MP4A) and PET. Donepezil 29-52 acetylcholinesterase (Cartwright blood group) Homo sapiens 63-83 15920507-1 2005 Donepezil hydrochloride is a potent and selective inhibitor for brain acetylcholinesterase (AChE) and is currently used worldwide for the treatment of Alzheimer"s disease. Donepezil 0-23 acetylcholinesterase (Cartwright blood group) Homo sapiens 70-90 15920507-1 2005 Donepezil hydrochloride is a potent and selective inhibitor for brain acetylcholinesterase (AChE) and is currently used worldwide for the treatment of Alzheimer"s disease. Donepezil 0-23 acetylcholinesterase (Cartwright blood group) Homo sapiens 92-96 15920507-3 2005 The purpose of this study was to estimate in vivo plasma IC(50) of donepezil in living monkeys by measuring plasma donepezil concentration (LC/MS/MS) and brain AChE activity with positron emission tomography (PET) and N-[(11)C]methylpiperidin-4-yl acetate, which is an acetylcholine analog recently developed by us for quantifying in vivo brain AChE activity. Donepezil 67-76 acetylcholinesterase (Cartwright blood group) Homo sapiens 160-164 15920507-3 2005 The purpose of this study was to estimate in vivo plasma IC(50) of donepezil in living monkeys by measuring plasma donepezil concentration (LC/MS/MS) and brain AChE activity with positron emission tomography (PET) and N-[(11)C]methylpiperidin-4-yl acetate, which is an acetylcholine analog recently developed by us for quantifying in vivo brain AChE activity. Donepezil 67-76 acetylcholinesterase (Cartwright blood group) Homo sapiens 345-349 15920507-6 2005 The plasma donepezil concentrations 14 min after intravenous injection were proportional to the doses, 17.2+/-2.9 ng/ml (donepezil-1) and 44.0+/-5.0 ng/ml (donepezil-2), and the mean AChE inhibitions in four neocortical regions as evaluated by PET were also dose-dependent, 27% (donepezil-1) and 53% (donepezil-2). Donepezil 11-20 acetylcholinesterase (Cartwright blood group) Homo sapiens 183-187 19595845-0 2005 Reversal of scopolamine-induced deficits with a single dose of donepezil, an acetylcholinesterase inhibitor. Donepezil 63-72 acetylcholinesterase (Cartwright blood group) Homo sapiens 77-97 16190917-3 2005 The effect of donepezil, a cholinesterase inhibitor on memory functions was tested in an open-label, exploratory study in 11 patients with a chronic amnestic syndrome from a ruptured and repaired aneurysm of the anterior communicating artery (seven patients), the anterior cerebral (two) or the pericallosal artery (two). Donepezil 14-23 butyrylcholinesterase Homo sapiens 27-41 16863459-1 2005 Donepezil is a selective acetylcholinesterase inhibitor that is widely prescribed for Alzheimer"s disease (AD). Donepezil 0-9 acetylcholinesterase (Cartwright blood group) Homo sapiens 25-45 15951396-11 2005 It was concluded that donepezil at low therapeutic concentrations (0.01-1 microM) potentiated the activity of the NMDA system and that this action together with cholinesterase inhibition would contribute to the improvement of learning, memory, and cognition in patients with Alzheimer"s disease. Donepezil 22-31 butyrylcholinesterase Homo sapiens 161-175 16485632-0 2005 Potassium channel modulation by acetylcholinesterase inhibitor donepezil. Donepezil 63-72 acetylcholinesterase (Cartwright blood group) Homo sapiens 32-52 15630600-6 2005 We observed a clear-cut relationship between the occurrence of nightmares and an evening dose of donepezil in eight patients with DAT. Donepezil 97-106 solute carrier family 6 member 3 Homo sapiens 130-133 15630600-8 2005 We suggest that the activation of the visual association cortex during REM sleep is enhanced by donepezil, a mechanism most likely facilitating the development of nightmares in patients with DAT. Donepezil 96-105 solute carrier family 6 member 3 Homo sapiens 191-194 16081444-2 2005 Three cholinesterase inhibitors are currently recommended: donepezil, rivastigmine, and galantamine. Donepezil 59-68 butyrylcholinesterase Homo sapiens 6-20 16045972-5 2005 To test this hypothesis, we evaluated the effects of chronic donepezil, nicotine and haloperidol on expression levels of 5-HT2A mRNA and 5-HT2A receptor density in select brain regions. Donepezil 61-70 5-hydroxytryptamine (serotonin) receptor 2A Mus musculus 121-127 16045972-9 2005 Donepezil significantly increased 5-HT2A mRNA level, but not the receptor density in the striatum. Donepezil 0-9 5-hydroxytryptamine (serotonin) receptor 2A Mus musculus 34-40 16045972-12 2005 The cortex was the only area where donepezil, nicotine and haloperidol significantly reduced the 5-HT2A receptor density. Donepezil 35-44 5-hydroxytryptamine (serotonin) receptor 2A Mus musculus 97-112 16045972-13 2005 The results suggest that the anti-tic properties of donepezil, nicotine and haloperidol in this paradigm might be due to antagonism of cortical 5-HT2A receptors. Donepezil 52-61 5-hydroxytryptamine (serotonin) receptor 2A Mus musculus 144-150 16054679-2 2005 This study evaluated the effects of pretreatment with the oral cholinesterase inhibitor and anti-Alzheimer"s agent, donepezil (Aricept) on the hypokinetic, hypothermic and diarrhea-inducing effects of the irreversible long-acting cholinesterase inhibitor, diisopropylfluorophosphate (DFP) in adult Sprague-Dawley rats. Donepezil 116-125 butyrylcholinesterase Rattus norvegicus 230-244 16054679-2 2005 This study evaluated the effects of pretreatment with the oral cholinesterase inhibitor and anti-Alzheimer"s agent, donepezil (Aricept) on the hypokinetic, hypothermic and diarrhea-inducing effects of the irreversible long-acting cholinesterase inhibitor, diisopropylfluorophosphate (DFP) in adult Sprague-Dawley rats. Donepezil 127-134 butyrylcholinesterase Rattus norvegicus 230-244 15778881-4 2005 OBJECTIVES: The effects of administration of two acetylcholinesterase inhibitors, physostigmine and donepezil, on Abeta plaque formation and memory-related behaviors were investigated in the Tg2576-transgenic mouse model of AD. Donepezil 100-109 amyloid beta precursor protein Homo sapiens 114-119 16548656-3 2005 The primary objective of this article is to review the recent data demonstrating that patients with advanced AD can benefit from treatment with the cholinesterase inhibitor donepezil. Donepezil 173-182 butyrylcholinesterase Homo sapiens 148-162 15829527-9 2005 Among carriers of one or more apolipoprotein E epsilon4 alleles, the benefit of donepezil was evident throughout the three-year follow-up. Donepezil 80-89 apolipoprotein E Homo sapiens 30-55 16129386-1 2005 BACKGROUND: Clinical studies have shown efficacy of cholinesterase inhibitors (eg, donepezil) in mild to moderate Alzheimer"s disease (AD). Donepezil 83-92 butyrylcholinesterase Homo sapiens 52-66 15800138-1 2005 OBJECTIVE: The only approved pharmacological approach for the symptomatic treatment of Alzheimer"s disease in Japan is the use of a cholinesterase inhibitor, donepezil hydrochloride. Donepezil 158-181 butyrylcholinesterase Homo sapiens 132-146 15738747-1 2005 Neuropsychological performance was examined in healthy elderly participants administered the cholinesterase inhibitor donepezil. Donepezil 118-127 butyrylcholinesterase Homo sapiens 93-107 15760632-2 2005 The cholinesterase inhibitor, donepezil, is clinically effective in both AD and VaD. Donepezil 30-39 butyrylcholinesterase Homo sapiens 4-18 15966445-1 2005 The AD2000 study was a randomized placebo-controlled trial, the effects of donepezil, a cholinesterase inhibitor, in patients with Alzheimer"s disease. Donepezil 75-84 butyrylcholinesterase Homo sapiens 88-102 15596427-0 2005 Acetylcholinesterase inhibitors for the treatment of Wernicke-Korsakoff syndrome--three further cases show response to donepezil. Donepezil 119-128 acetylcholinesterase (Cartwright blood group) Homo sapiens 0-20 15596427-1 2005 Three patients diagnosed with Wernicke-Korsakoff syndrome were treated with the acetylcholinesterase inhibitor, donepezil, for periods of 6 to 8 months. Donepezil 112-121 acetylcholinesterase (Cartwright blood group) Homo sapiens 80-100 15935590-5 2005 After 1 month of therapy with AchEI (Donepezil), MCP-1 levels increased in each patient. Donepezil 37-46 C-C motif chemokine ligand 2 Homo sapiens 49-54 15935590-6 2005 However, higher levels were detected for RANTES in AD patients compared to control subjects and in AD patients treated with Donepezil. Donepezil 124-133 C-C motif chemokine ligand 5 Homo sapiens 41-47 15965198-1 2005 OBJECTIVE: To study the safety and efficacy of a cholinesterase inhibitor, donepezil hydrochloride, for the treatment of dementia in Parkinson"s disease (PD). Donepezil 75-98 butyrylcholinesterase Homo sapiens 49-63 15893738-1 2005 Donepezil, a potent acetylcholinesterase (AChE) inhibitor used for the treatment of Alzheimer"s disease (AD), is thought to have a neuroprotective effect in AD patients. Donepezil 0-9 acetylcholinesterase (Cartwright blood group) Homo sapiens 42-46 15893738-7 2005 These results suggest that donepezil exerts a neuroprotective effect by reducing the amount of the toxic form of Abeta fibrils in septal neuron cultures. Donepezil 27-36 amyloid beta precursor protein Rattus norvegicus 113-118 15654502-8 2005 RESULTS: All cholinesterase inhibitors reduced cognitive deficits with the following optimal daily doses: galantamine 1.25 mg kg(-1), rivastigmine 0.5 mg kg(-1) and donepezil 0.3 mg kg(-1). Donepezil 165-174 butyrylcholinesterase Homo sapiens 13-27 15848214-6 2005 The present study was designed to investigate the influence of chronic administration of donepezil (cholinesterase inhibitor, 1 and 3 mg/kg) and lercanidipine (L-type calcium channel blocker, 0.3 and 1 mg/kg) on cognitive impairment in male Sprague-Dawley rats injected twice with ICV STZ (3 mg/kg) bilaterally on days 1 and 3. Donepezil 89-98 butyrylcholinesterase Rattus norvegicus 100-114 15848214-9 2005 Donepezil dose-dependently inhibited cholinesterase activity and improved performance in memory tests at both the doses. Donepezil 0-9 butyrylcholinesterase Rattus norvegicus 37-51 15862539-0 2005 Neuroprotective effect of donepezil, a nicotinic acetylcholine-receptor activator, on cerebral infarction in rats. Donepezil 26-35 cholinergic receptor nicotinic alpha 2 subunit Rattus norvegicus 39-71 15862539-1 2005 This study evaluated the potential effect of donepezil, which is known as an acetylcholinesterase inhibitor used for treatment of Alzheimer"s disease, against cerebral infarction induced by permanent left middle cerebral artery (MCA) occlusion. Donepezil 45-54 acetylcholinesterase Rattus norvegicus 77-97 15763392-3 2005 The present study was designed as a randomised controlled trial to evaluate long term effects of donepezil, a cerebral selective ChEI, on basal GH and IGF-1 levels and on GH response to GHRH (1 microg/kg i.v., GHRH test) before and after an 8-week donepezil treatment period. Donepezil 97-106 insulin like growth factor 1 Homo sapiens 151-156 15763392-9 2005 This study demonstrated that the age-related down-regulation of the GH/IGF-1 axis is reversed considerably by donepezil in the elderly male. Donepezil 110-119 insulin like growth factor 1 Homo sapiens 71-76 15863734-3 2005 The cholinesterase inhibitors donepezil hydrochloride, galantamine hydrobromide, and rivastigmine tartrate are the current mainstays of symptomatic treatment for patients with AD. Donepezil 30-53 butyrylcholinesterase Homo sapiens 4-18 15716518-3 2005 RESULTS: Analysis of the PET data revealed mean (temporal, parietal, and frontal) cortical donepezil induced AChE inhibition of 19.1% (SD 9.4%) (t = -7.9; p<0.0001). Donepezil 91-100 acetylcholinesterase (Cartwright blood group) Homo sapiens 109-113 15716518-5 2005 Donepezil induced cortical inhibition of AChE activity correlated with changes in the Stroop Color Word interference scores (R(2) = 0.59, p<0.01), but not with primary memory test scores. Donepezil 0-9 acetylcholinesterase (Cartwright blood group) Homo sapiens 41-45 15716518-7 2005 CONCLUSIONS: Donepezil induced inhibition of cortical AChE enzyme activity is modest in patients with mild AD. Donepezil 13-22 acetylcholinesterase (Cartwright blood group) Homo sapiens 54-58 15710875-5 2005 Treatment aimed to restore acetylcholine content through chronic administration of selective acetylcholinesterase inhibitors (rivastigmine and donepezil) restores cognitive performance, choline acetyltransferase activity, and nerve growth factor mRNA expression. Donepezil 143-152 choline O-acetyltransferase Rattus norvegicus 186-211 15710875-5 2005 Treatment aimed to restore acetylcholine content through chronic administration of selective acetylcholinesterase inhibitors (rivastigmine and donepezil) restores cognitive performance, choline acetyltransferase activity, and nerve growth factor mRNA expression. Donepezil 143-152 nerve growth factor Rattus norvegicus 226-245 15704966-5 2005 This method was further applied to the synthesis of 1-tetralones, 1-benzosuberones, and the potent acetylcholinesterase inhibitor donepezil. Donepezil 130-139 acetylcholinesterase (Cartwright blood group) Homo sapiens 99-119 16192723-2 2005 The objective of this study was to determine if treatment with donepezil, an acetylcholinesterase inhibitor, may provide benefit for VaD patients. Donepezil 63-72 acetylcholinesterase (Cartwright blood group) Homo sapiens 77-97 15694923-0 2005 Brain levels and acetylcholinesterase inhibition with galantamine and donepezil in rats, mice, and rabbits. Donepezil 70-79 acetylcholinesterase Rattus norvegicus 17-37 15694923-2 2005 Earlier data from in vitro biochemical tests suggest that donepezil is 40- to 500-fold more potent than galantamine in inhibiting AChE. Donepezil 58-67 acetylcholinesterase Rattus norvegicus 130-134 15694923-3 2005 In this study, both brain levels and Ki values for AChE inhibition for donepezil and galantamine in rat, mouse, and rabbit after subcutaneous application were determined. Donepezil 71-80 acetylcholinesterase Rattus norvegicus 51-55 15694923-7 2005 Ki values of brain AChE inhibition for galantamine and donepezil, respectively, are 7.1 and 2.3 microg/g in rats, 8.3 and 0.65 microg/g for mice, and 19.1 and 1.3 microg/g in rabbits. Donepezil 55-64 acetylcholinesterase Rattus norvegicus 19-23 15680250-4 2005 Donepezil reversibly inhibited voltage-activated Na+ current (I(Na)), delayed rectifier K+ current (I(K)) and fast transient K+ current (I(A)). Donepezil 0-9 internexin neuronal intermediate filament protein, alpha Rattus norvegicus 31-67 15474645-0 2005 Effects of the cholinesterase inhibitors donepezil and metrifonate on scopolamine-induced impairments in the spatial cone field orientation task in rats. Donepezil 41-50 butyrylcholinesterase Rattus norvegicus 15-29 16103669-0 2005 Apolipoprotein E epsilon4 allele differentiates the clinical response to donepezil in Alzheimer"s disease. Donepezil 73-82 apolipoprotein E Homo sapiens 0-25 16103669-9 2005 We evaluated the possible effect of the APOE genotype on the neuropsychological tasks in relation to donepezil therapy. Donepezil 101-110 apolipoprotein E Homo sapiens 40-44 16192723-6 2005 RESULTS: Both donepezil groups showed significant improvements in cognition compared with placebo (ADAS-cog, MMSE, p < 0.01). Donepezil 14-23 alkylglycerone phosphate synthase Homo sapiens 99-103 15605367-7 2005 The second assessment (3 months after donepezil) showed a decrease in the ADAS-cog score to 23.3 (11-35) though without statistical significance. Donepezil 38-47 alkylglycerone phosphate synthase Homo sapiens 74-78 15708480-6 2005 The wake-promoting efficacy of the acetylcholinesterase inhibitor donepezil was lower in plaque-bearing Tg2576 mice than in controls. Donepezil 66-75 acetylcholinesterase Mus musculus 35-55 17203561-18 2005 Donepezil and galantamine were the preferred cholinesterase inhibitors. Donepezil 0-9 butyrylcholinesterase Homo sapiens 45-59 16336020-1 2005 OBJECTIVE: To estimate the cost effectiveness (from the UK NHS and personal social services perspective) of the cholinesterase inhibitors donepezil, rivastigmine and galantamine compared with usual care in the treatment of mild to moderately severe Alzheimer"s disease. Donepezil 138-147 butyrylcholinesterase Homo sapiens 112-126 22034396-2 2004 Randomized clinical trials comparing the acetylcholinesterase inhibitor donepezil with placebo have shown some symptomatic benefit on (i) cognition in one short-term (6-month) study; and (ii)conversion to dementia in one long-term (3-year) study, but not for the full duration of the study, except in subjects with the apolipoprotein E4 (APOE-4) mutation, in whoom the benefit was sustained throughout the 3 years. Donepezil 72-81 acetylcholinesterase (Cartwright blood group) Homo sapiens 41-61 22034396-2 2004 Randomized clinical trials comparing the acetylcholinesterase inhibitor donepezil with placebo have shown some symptomatic benefit on (i) cognition in one short-term (6-month) study; and (ii)conversion to dementia in one long-term (3-year) study, but not for the full duration of the study, except in subjects with the apolipoprotein E4 (APOE-4) mutation, in whoom the benefit was sustained throughout the 3 years. Donepezil 72-81 apolipoprotein E Homo sapiens 319-336 22034396-2 2004 Randomized clinical trials comparing the acetylcholinesterase inhibitor donepezil with placebo have shown some symptomatic benefit on (i) cognition in one short-term (6-month) study; and (ii)conversion to dementia in one long-term (3-year) study, but not for the full duration of the study, except in subjects with the apolipoprotein E4 (APOE-4) mutation, in whoom the benefit was sustained throughout the 3 years. Donepezil 72-81 apolipoprotein E Homo sapiens 338-344 15567429-0 2004 Novel neuronal targets for the acetylcholinesterase inhibitor donepezil. Donepezil 62-71 acetylcholinesterase (Cartwright blood group) Homo sapiens 31-51 15567429-1 2004 The effects of the acetylcholinesterase inhibitor donepezil on cell viability and proliferation events have been analysed in SH-SY5Y human neuroblastoma cells. Donepezil 50-59 acetylcholinesterase (Cartwright blood group) Homo sapiens 19-39 15567429-4 2004 In addition, the expression of two cyclins of the G1/S and G2/M transitions, cyclin E and cyclin B, was significantly reduced in donepezil-treated cells. Donepezil 129-138 proline rich protein BstNI subfamily 3 Homo sapiens 50-63 15567429-6 2004 Finally, donepezil increased the expression of the neuronal marker MAP-2 in selected subpopulations of SH-SY5Y cells, suggesting that the effect on cell proliferation by donepezil may correlate to a trend to neuronal differentiation. Donepezil 9-18 microtubule associated protein 2 Homo sapiens 67-72 15567429-6 2004 Finally, donepezil increased the expression of the neuronal marker MAP-2 in selected subpopulations of SH-SY5Y cells, suggesting that the effect on cell proliferation by donepezil may correlate to a trend to neuronal differentiation. Donepezil 170-179 microtubule associated protein 2 Homo sapiens 67-72 15496218-15 2004 CONCLUSIONS: The results of this study suggest that patients with AD and mild to moderate hepatic impairment (Child-Pugh grade A or B) can be safely given donepezil 5 mg once daily and that this dose is associated with a nonsignificantly higher AChE inhibition than age-matched volunteers. Donepezil 155-164 acetylcholinesterase (Cartwright blood group) Homo sapiens 245-249 15480840-8 2004 Recent studies with the cholinesterase inhibitors galantamine, donepezil and rivastigmine show promising results in improving cognition and ameliorating psychotic symptoms, which must further be confirmed in randomized controlled trials. Donepezil 63-72 butyrylcholinesterase Homo sapiens 24-38 15537474-6 2004 On the ADL, donepezil- and galantamine-treated patients showed decreases of 0.44 and 0.86 points, respectively, while there was "no change" with rivastigmine. Donepezil 12-21 sarcoglycan alpha Homo sapiens 7-10 15496314-2 2004 Other acetylcholinesterase inhibitors also increased the twitches, showing a hierarchy of potencies of galantamine>physostigmine>tacrine>rivastigmine=donepezil. Donepezil 159-168 acetylcholinesterase Rattus norvegicus 6-26 15472779-0 2004 [Doubtful evidence for the use of the cholinesterase inhibitor donepezil in patients with dementia--a systematic review]. Donepezil 63-72 butyrylcholinesterase Homo sapiens 38-52 15449367-1 2004 OBJECTIVES: Clinical trials of the cholinesterase inhibitor donepezil have used standard psychometric tools to evaluate treatment efficacy. Donepezil 60-69 butyrylcholinesterase Homo sapiens 35-49 15304241-1 2004 The therapeutic approach for improving the cognitive function in patients with Alzheimer"s disease (AD) is mainly based on the potentiation of central cholinergic activity and is achieved clinically by the use of acetylcholinesterase (AChE) inhibitors such as tacrine, donepezil, rivastigmine, galantamine and other drugs currently in clinical trials. Donepezil 269-278 acetylcholinesterase (Cartwright blood group) Homo sapiens 213-233 15304241-1 2004 The therapeutic approach for improving the cognitive function in patients with Alzheimer"s disease (AD) is mainly based on the potentiation of central cholinergic activity and is achieved clinically by the use of acetylcholinesterase (AChE) inhibitors such as tacrine, donepezil, rivastigmine, galantamine and other drugs currently in clinical trials. Donepezil 269-278 acetylcholinesterase (Cartwright blood group) Homo sapiens 235-239 15241294-4 2004 Cholinesterase (ChE) inhibitors, such as donepezil, rivastigmine, and galantamine, cause symptomatic improvement by inhibiting the breakdown of the neurotransmitter acetylcholine to increase its synaptic availability and, in the case of galantamine, by also allosterically potentiating nicotinic cholinergic receptors. Donepezil 41-50 butyrylcholinesterase Homo sapiens 0-14 15335298-1 2004 The "second-generation" cholinesterase inhibitors (ChEIs), donepezil, galantamine and rivastigmine, are a class of medications that are currently approved for the treatment of mild-to-moderate Alzheimer"s disease (AD). Donepezil 59-68 butyrylcholinesterase Homo sapiens 24-38 15341532-4 2004 In these cells, the activity of AChE is significantly decreased after 2 h of donepezil treatment. Donepezil 77-86 acetylcholinesterase (Cartwright blood group) Homo sapiens 32-36 15341532-7 2004 This effect was prevented by pretreatment with tunicamycin or brefeldin, suggesting that donepezil affects trafficking and/or maturation of ADAM 10; additionally, this pretreatment significantly decreased sAPPalpha levels. Donepezil 89-98 ADAM metallopeptidase domain 10 Homo sapiens 140-147 15472417-4 2004 Cholinesterase inhibitors such as donepezil and rivastigmine have been shown to provide symptomatic relief in patients with AD but have no effect on disease progression or survival. Donepezil 34-43 butyrylcholinesterase Homo sapiens 0-14 15333988-4 2004 Donepezil suppressed AChE activity, analyzed by [(11)C]MP4A, in all cortical regions in a dose-dependent manner. Donepezil 0-9 acetylcholinesterase (Cartwright blood group) Homo sapiens 21-25 15333988-5 2004 AChE inhibition by donepezil resulted in a dose-dependent increase in acetylcholine levels in the prefrontal cortex as measured by microdialysis. Donepezil 19-28 acetylcholinesterase (Cartwright blood group) Homo sapiens 0-4 15333988-8 2004 As evaluated by an oculomotor delayed response task, aged monkeys showed impaired working memory performance compared to young monkeys, and the impaired performance was partly improved by the administration of donepezil, due to the facilitation of the cholinergic neuronal system by AChE inhibition by donepezil. Donepezil 210-219 acetylcholinesterase (Cartwright blood group) Homo sapiens 283-287 15266045-2 2004 OBJECTIVE: To determine whether an in vivo pharmacokinetic interaction exists between memantine and the acetylcholinesterase (AChE) inhibitor donepezil. Donepezil 142-151 acetylcholinesterase (Cartwright blood group) Homo sapiens 126-130 15266045-7 2004 In addition, AChE inhibition was measured in red blood cells by radiolabeled-enzyme assay following administration of donepezil alone and after a single memantine dose. Donepezil 118-127 acetylcholinesterase (Cartwright blood group) Homo sapiens 13-17 15266045-9 2004 Percent maximum inhibition of AChE activity (mean +/- SD) by donepezil was 77.8 +/- 7.3% and not significantly different upon coadministration of a single dose of memantine (81.1 +/- 5.7%). Donepezil 61-70 acetylcholinesterase (Cartwright blood group) Homo sapiens 30-34 15326237-9 2004 More donepezil-treated patients showed improvements in ADAS-cog total scores, in tests of attention and psychomotor speed, and in PGA scores. Donepezil 5-14 alkylglycerone phosphate synthase Homo sapiens 55-59 15241749-10 2004 RESULTS: Intragroup comparison of different phases of the trial in both groups showed that donepezil significantly increased the testing scores of the AII and VII, as well as PASAT scores, compared with baseline. Donepezil 91-100 NLR family pyrin domain containing 3 Homo sapiens 151-162 15241294-4 2004 Cholinesterase (ChE) inhibitors, such as donepezil, rivastigmine, and galantamine, cause symptomatic improvement by inhibiting the breakdown of the neurotransmitter acetylcholine to increase its synaptic availability and, in the case of galantamine, by also allosterically potentiating nicotinic cholinergic receptors. Donepezil 41-50 butyrylcholinesterase Homo sapiens 16-19 15237749-4 2004 Indeed, several recent clinical trials of donepezil, galanthamine and rivastigmine have come to the conclusion that these cholinesterase inhibitors have overall beneficial effects in cognitive as well as global functions. Donepezil 42-51 butyrylcholinesterase Homo sapiens 122-136 15252826-2 2004 Donepezil, a central cholinesterase inhibitor, improves psychotic symptomatology in demented patients, however, evidence for its role in the management of active psychosis in schizophrenia remains limited. Donepezil 0-9 butyrylcholinesterase Homo sapiens 21-35 15558381-1 2004 Donepezil, a primarily central acetylcholinesterase inhibitor, could potentiate learning in subjects with stroke by amplifying cholinergic input to the cerebral cortex from the nucleus basalis of Meynert. Donepezil 0-9 acetylcholinesterase (Cartwright blood group) Homo sapiens 31-51 15118486-4 2004 Patients were assessed for clinical and immunologic features at baseline and after 1 month of treatment with Donepezil, an acetylcholinesterase inhibitor. Donepezil 109-118 acetylcholinesterase (Cartwright blood group) Homo sapiens 123-143 15118486-8 2004 Compared with untreated patients and healthy control subjects, IL-1beta levels and expression decreased in Alzheimer disease patients treated with Donepezil (P < 0.001). Donepezil 147-156 interleukin 1 alpha Homo sapiens 63-71 15094325-8 2004 Furthermore, anti-dementia drugs (such as Cognex and Aricept) markedly depress the expression of this pro-apoptotic GAPDH promoter activity. Donepezil 53-60 glyceraldehyde-3-phosphate dehydrogenase Homo sapiens 116-121 15258780-8 2004 In patients with dementia associated with PD cognitive functioning and behavioural problems appear to respond to cholinesterase inhibitors, such as rivastigmine or donepezil. Donepezil 164-173 butyrylcholinesterase Homo sapiens 113-127 14755627-1 2004 This study demonstrated the effects of acute acetylcholinesterase (AChE) inhibition by donepezil (Aricept) on the cerebral cholinergic neuronal system in the brains of young (5.2 +/- 1.1 years old) and aged (20.3 +/- 2.6 years old) monkeys (Macaca mulatta) in the conscious state. Donepezil 87-96 acetylcholinesterase Macaca mulatta 45-65 14755627-1 2004 This study demonstrated the effects of acute acetylcholinesterase (AChE) inhibition by donepezil (Aricept) on the cerebral cholinergic neuronal system in the brains of young (5.2 +/- 1.1 years old) and aged (20.3 +/- 2.6 years old) monkeys (Macaca mulatta) in the conscious state. Donepezil 87-96 acetylcholinesterase Macaca mulatta 67-71 14755627-1 2004 This study demonstrated the effects of acute acetylcholinesterase (AChE) inhibition by donepezil (Aricept) on the cerebral cholinergic neuronal system in the brains of young (5.2 +/- 1.1 years old) and aged (20.3 +/- 2.6 years old) monkeys (Macaca mulatta) in the conscious state. Donepezil 98-105 acetylcholinesterase Macaca mulatta 45-65 14755627-1 2004 This study demonstrated the effects of acute acetylcholinesterase (AChE) inhibition by donepezil (Aricept) on the cerebral cholinergic neuronal system in the brains of young (5.2 +/- 1.1 years old) and aged (20.3 +/- 2.6 years old) monkeys (Macaca mulatta) in the conscious state. Donepezil 98-105 acetylcholinesterase Macaca mulatta 67-71 14755627-2 2004 Donepezil at doses of 50 and 250 microg/kg suppressed AChE activity, analyzed by metabolic rate (k(3)) of N-[(11)C]methyl-4-piperidyl acetate ([(11)C]MP4A), in all cortical regions in a dose-dependent manner in both age groups. Donepezil 0-9 acetylcholinesterase Macaca mulatta 54-58 14755627-4 2004 AChE inhibition by donepezil resulted in a dose-dependent increase in acetylcholine levels in the prefrontal cortex of young animals as measured by microdialysis. Donepezil 19-28 acetylcholinesterase Macaca mulatta 0-4 14755627-7 2004 As evaluated by an oculomotor delayed response task, aged monkeys showed impaired working memory performance compared to young monkeys, and the impaired performance was partly improved by the administration of donepezil, due to the facilitation of the cholinergic neuronal system by AChE inhibition. Donepezil 210-219 acetylcholinesterase Macaca mulatta 283-287 15059034-4 2004 METHODS: We applied the phenotypic screening process to an analysis of the m1 muscarinic acetylcholine receptor (CHRM1) gene in a cohort of 74 individuals, including 48 diagnosed with neurodegenerative disease, primarily Alzheimer disease, who have been stratified according to their clinical response to the acetylcholinesterase inhibitor donepezil. Donepezil 340-349 cholinergic receptor muscarinic 1 Homo sapiens 113-118 15119476-3 2004 Observations of improved behavior and language output from prior open-label and double-blind treatment of autistic children with donepezil, another cholinesterase inhibitor, prompted this 12-week open-label study with rivastigmine tartrate of 32 autistic patients. Donepezil 129-138 butyrylcholinesterase Homo sapiens 148-162 14751462-2 2004 The current study evaluated the effects of pretreatment with the oral anticholinesterase agent, donepezil (Aricept, 2.0 mg/kg), used to treat Alzheimer"s disease, with and without scopolamine in decreasing the hypothermic, hypokinetic, and diarrhea-inducing effects of the irreversible long-acting cholinesterase inhibitor diisopropyl fluorophosphate (DFP, 1.0 mg/kg) in adult Flinders sensitive line (FSL) male rats. Donepezil 96-105 butyrylcholinesterase Rattus norvegicus 74-88 14751462-2 2004 The current study evaluated the effects of pretreatment with the oral anticholinesterase agent, donepezil (Aricept, 2.0 mg/kg), used to treat Alzheimer"s disease, with and without scopolamine in decreasing the hypothermic, hypokinetic, and diarrhea-inducing effects of the irreversible long-acting cholinesterase inhibitor diisopropyl fluorophosphate (DFP, 1.0 mg/kg) in adult Flinders sensitive line (FSL) male rats. Donepezil 107-114 butyrylcholinesterase Rattus norvegicus 74-88 14751462-5 2004 Therefore, these preliminary findings are encouraging, but many additional studies are needed to establish the effectiveness of donepezil as a prophylactic agent against irreversible cholinesterase inhibition by DFP. Donepezil 128-137 butyrylcholinesterase Rattus norvegicus 183-197 14728055-1 2004 Two of the four licensed cholinesterase inhibitors, galantamine and donepezil, have recently featured in published work showing how they act in dementia associated with cerebrovascular disease (CVD). Donepezil 68-77 butyrylcholinesterase Homo sapiens 25-39 15134572-8 2004 Both [(11)C]MP4A- and [(11)C]MP4P-PET have demonstrated not only the reduction of AChE activity in the cerebral cortex of patients with Alzheimer"s disease (AD) but also the inhibitory effects of donepezil and rivastigmine on AChE activity in the brain of AD patients. Donepezil 196-205 acetylcholinesterase (Cartwright blood group) Homo sapiens 226-230 15544502-3 2004 Effectiveness in AChE inhibition and side-effect issues of clinical (tacrine, donepezil, galanthamine and rivastigmine) as well as of novel inhibitors is reviewed here. Donepezil 78-87 acetylcholinesterase (Cartwright blood group) Homo sapiens 17-21 14974068-5 2004 Cholinesterase inhibitors, such as donepezil, may therefore be a rational treatment. Donepezil 35-44 butyrylcholinesterase Homo sapiens 0-14 14560059-1 2004 In the present study, the socioeconomic impact of the use of the acetylcholinesterase inhibitor donepezil in patients with mild to moderate Alzheimer"s disease (AD) living in France was examined. Donepezil 96-105 acetylcholinesterase (Cartwright blood group) Homo sapiens 65-85 15544507-2 2004 Thus, it is not surprising that the first therapeutic target that has demonstrated therapeutic efficacy on cognition, behaviour and functional daily activities has been the inhibitors of acetylcholinesterase (AChE), i.e. tacrine, donepezil, rivastigmine and galanthamine. Donepezil 230-239 acetylcholinesterase (Cartwright blood group) Homo sapiens 209-213 14716700-7 2004 Significantly greater improvements in cognition were also observed for donepezil versus galantamine on the ADAS-cog at Week 12 and endpoint (p-values <0.05). Donepezil 71-80 alkylglycerone phosphate synthase Homo sapiens 107-111 15132713-4 2004 There is substantial evidence that the cholinesterase inhibitors, including donepezil, galantamine and rivastigmine, decrease acetylcholinesterase activity in a number of brain regions in patients with Alzheimer"s disease. Donepezil 76-85 butyrylcholinesterase Homo sapiens 39-53 15132713-4 2004 There is substantial evidence that the cholinesterase inhibitors, including donepezil, galantamine and rivastigmine, decrease acetylcholinesterase activity in a number of brain regions in patients with Alzheimer"s disease. Donepezil 76-85 acetylcholinesterase (Cartwright blood group) Homo sapiens 126-146 15132713-13 2004 Certainly, as a class, the currently approved cholinesterase inhibitors (donepezil, galantamine, rivastigmine and tacrine) provide important benefits in patients with Alzheimer"s disease and these drugs offer a significant advance in the management of dementia. Donepezil 73-82 butyrylcholinesterase Homo sapiens 46-60 15314255-1 2004 Donepezil (Aricept), a long-acting cholinesterase inhibitor, is widely used in the treatment of Alzheimer"s disease to improve cognition and memory. Donepezil 0-9 butyrylcholinesterase Macaca mulatta 35-49 14964575-4 2004 In contrast, only one acetylcholinesterase inhibitor, donepezil has been proven effective and used for patients with mild or moderate Alzheimer"s disease in Japan. Donepezil 54-63 acetylcholinesterase (Cartwright blood group) Homo sapiens 22-42 15314255-1 2004 Donepezil (Aricept), a long-acting cholinesterase inhibitor, is widely used in the treatment of Alzheimer"s disease to improve cognition and memory. Donepezil 11-18 butyrylcholinesterase Macaca mulatta 35-49 14675494-1 2003 BACKGROUND: Cholinesterase inhibitors, such as galantamine, donepezil and rivastigmine are approved for symptomatic treatment of Alzheimer"s Disease (AD) in Canada. Donepezil 60-69 butyrylcholinesterase Homo sapiens 12-26 14561111-1 2003 Our goal in this study was to determine whether donepezil, an acetylcholinesterase inhibitor, would improve cognitive functioning in 19 subjects with Down syndrome and no dementia. Donepezil 48-57 acetylcholinesterase (Cartwright blood group) Homo sapiens 62-82 14757932-0 2003 Effects of donepezil treatment on rat nicotinic acetylcholine receptor levels in vivo and in vitro. Donepezil 11-20 cholinergic receptor nicotinic alpha 2 subunit Rattus norvegicus 38-70 14757932-10 2003 These results indicate that donepezil increases cortical alpha 7 and non-alpha 7 nAChRs, hippocampal non-alpha 7 nAChRs but does not influence striatal nAChR levels. Donepezil 28-37 cholinergic receptor nicotinic beta 1 subunit Rattus norvegicus 81-86 12955395-1 2003 The interaction between human serum albumin (HSA) and the acetylcholinesterase inhibitor donepezil, has been studied by means of capillary electrophoresis frontal analysis (CE/FA) and circular dichroism. Donepezil 89-98 albumin Homo sapiens 30-49 12955395-1 2003 The interaction between human serum albumin (HSA) and the acetylcholinesterase inhibitor donepezil, has been studied by means of capillary electrophoresis frontal analysis (CE/FA) and circular dichroism. Donepezil 89-98 acetylcholinesterase (Cartwright blood group) Homo sapiens 58-78 12955395-2 2003 CE/FA enabled rapid and direct estimation of the quantity of free donepezil present at equilibrium with a physiological level of serum albumin (600 micromol L(-1)). Donepezil 66-75 albumin Homo sapiens 129-143 12955395-3 2003 Application of Scatchard analysis enabled estimation of the binding parameters of HSA towards donepezil, such as association constant and number of binding sites on one protein molecule. Donepezil 94-103 albumin Homo sapiens 82-85 12955395-4 2003 Furthermore, due to enantioseparation ability shown by HSA on donepezil in CE mode, displacement experiments were carried out using ketoprofen and warfarin as coadditives to the HSA based running buffer. Donepezil 62-71 albumin Homo sapiens 55-58 12955395-4 2003 Furthermore, due to enantioseparation ability shown by HSA on donepezil in CE mode, displacement experiments were carried out using ketoprofen and warfarin as coadditives to the HSA based running buffer. Donepezil 62-71 albumin Homo sapiens 178-181 14594748-1 2003 OBJECTIVE: The authors examined the effect of the acetylcholinesterase inhibitor donepezil on magnetic resonance markers of neurodegeneration in Alzheimer"s disease. Donepezil 81-90 acetylcholinesterase (Cartwright blood group) Homo sapiens 50-70 15222774-3 2004 The first prospective, randomised, controlled trial of the cholinesterase inhibitor donepezil in more advanced Alzheimer"s disease has reported quite encouraging results, with further studies being undertaken. Donepezil 84-93 butyrylcholinesterase Homo sapiens 59-73 13129577-1 2003 Alzheimer"s disease (AD) has been treated with acetylcholinesterase (AChE) inhibitors such as donepezil. Donepezil 94-103 acetylcholinesterase (Cartwright blood group) Homo sapiens 47-67 12955395-5 2003 The addition of these compounds reduced the enantioresolution of donepezil by HSA only when used at high concentration. Donepezil 65-74 albumin Homo sapiens 78-81 13129577-1 2003 Alzheimer"s disease (AD) has been treated with acetylcholinesterase (AChE) inhibitors such as donepezil. Donepezil 94-103 acetylcholinesterase (Cartwright blood group) Homo sapiens 69-73 14753643-1 2003 We describe three cases of patients with Alzheimer"s disease who presented with cardiac syncope soon after initiation of a cholinesterase inhibitor therapy (donepezil). Donepezil 157-166 butyrylcholinesterase Homo sapiens 123-137 15088511-2 2003 The approach to the treatment of Alzheimer"s dementia has been greatly modified by the acetylcholinesterase inhibitor drugs, first donepezil (Aricept) and then rivastigmine (Exelon) and galantamine (Reminyl), and the ever-increasing number of demented people forces us to be familiar with their use. Donepezil 131-140 acetylcholinesterase (Cartwright blood group) Homo sapiens 87-107 12967063-3 2003 The authors report on 3 patients with long-standing PD who were treated with the cholinesterase inhibitor donepezil for the treatment of VHs. Donepezil 106-115 butyrylcholinesterase Homo sapiens 81-95 12941576-4 2003 Here, we review clinical features of the available cholinesterase inhibitors (donepezil, rivastigmine, and galantamine) including their pharmacological properties, the evidence for switching from one agent to another, "head to head" studies, and the emerging evidence for the use of memantine in AD. Donepezil 78-87 butyrylcholinesterase Homo sapiens 51-65 12914543-1 2003 The current pharmacological treatment of Alzheimer"s disease (AD) comes down to four marketed drugs (tacrine, donepezil, rivastigmine and galantamine) all of which are cholinesterase inhibitors, conforming to the cholinergic hypothesis. Donepezil 110-119 butyrylcholinesterase Homo sapiens 168-182 12734391-0 2003 Nicotinic acetylcholine receptor-mediated neuroprotection by donepezil against glutamate neurotoxicity in rat cortical neurons. Donepezil 61-70 cholinergic receptor nicotinic alpha 2 subunit Rattus norvegicus 0-32 12734391-1 2003 Donepezil is a potent and selective acetylcholinesterase (AChE) inhibitor developed for the treatment of Alzheimer"s disease. Donepezil 0-9 acetylcholinesterase Rattus norvegicus 36-56 12734391-1 2003 Donepezil is a potent and selective acetylcholinesterase (AChE) inhibitor developed for the treatment of Alzheimer"s disease. Donepezil 0-9 acetylcholinesterase Rattus norvegicus 58-62 12734391-5 2003 Among AChE inhibitors examined, donepezil and certain AChE inhibitors such as tacrine and galanthamine showed potent neuroprotective action, although physostigmine did not affect glutamate neurotoxicity. Donepezil 32-41 acetylcholinesterase Rattus norvegicus 6-10 12734391-6 2003 Neuroprotective action of donepezil was antagonized by mecamylamine, a nicotinic acetylcholine receptor (nAChR) antagonist, but not by scopolamine, a muscarinic acetylcholine receptor antagonist. Donepezil 26-35 cholinergic receptor nicotinic alpha 2 subunit Rattus norvegicus 71-103 12734391-6 2003 Neuroprotective action of donepezil was antagonized by mecamylamine, a nicotinic acetylcholine receptor (nAChR) antagonist, but not by scopolamine, a muscarinic acetylcholine receptor antagonist. Donepezil 26-35 cholinergic receptor nicotinic alpha 2 subunit Rattus norvegicus 105-110 12921925-1 2003 We present a case of delirium due to amitriptyline overdose, which resolved rapidly following initiation of the cholinesterase inhibitor donepezil. Donepezil 137-146 butyrylcholinesterase Homo sapiens 112-126 12837675-2 2003 METHODS: All patients were examined annually with standard neuropsychologic tests and received the cholinesterase inhibitor donepezil hydrochloride at a dose of 10 mg/day. Donepezil 124-147 butyrylcholinesterase Homo sapiens 99-113 12837144-2 2003 Upon admission to the nursing facility, the patient was diagnosed with relatively severe Alzheimer"s disease (AD)treated with the cholinesterase inhibitor donepezil in the context of a clinical study. Donepezil 155-164 butyrylcholinesterase Homo sapiens 130-144 12837144-3 2003 This report illustrates that donepezil, and perhaps by analogy other cholinesterase inhibitors as well, can be efficacious in treating the cognitive, functional, and behavioral impairment associated with advanced AD. Donepezil 29-38 butyrylcholinesterase Homo sapiens 69-83 15088511-2 2003 The approach to the treatment of Alzheimer"s dementia has been greatly modified by the acetylcholinesterase inhibitor drugs, first donepezil (Aricept) and then rivastigmine (Exelon) and galantamine (Reminyl), and the ever-increasing number of demented people forces us to be familiar with their use. Donepezil 142-149 acetylcholinesterase (Cartwright blood group) Homo sapiens 87-107 12794390-2 2003 The kinetic effects of the cholinesterase inhibitors donepezil, galantamine, metrifonate, physostigmine, rivastigmine, and tetrahydroaminoacridine were examined with respect to their action on the esterase and aryl acylamidase activities of human acetylcholinesterase (AChE) and human butyrylcholinesterase (BuChE). Donepezil 53-62 butyrylcholinesterase Homo sapiens 27-41 12649296-3 2003 The other presently approved AD drugs, donepezil and rivastigmine, are devoid of the nicotinic APL action; at micromolar concentrations they also block nAChR activity. Donepezil 39-48 cholinergic receptor nicotinic alpha 4 subunit Homo sapiens 152-157 24944370-1 2003 BACKGROUND: Cholinesterase (ChE) inhibitors currently used in the treatment of Alzheimer"s disease (AD) are the acetylcholinesterase (AChE)-selective inhibitors, donepezil and galantamine, and the dual AChE and butyrylcholinesterase (BuChE) inhibitor, rivastigmine. Donepezil 162-171 butyrylcholinesterase Homo sapiens 12-26 24944370-1 2003 BACKGROUND: Cholinesterase (ChE) inhibitors currently used in the treatment of Alzheimer"s disease (AD) are the acetylcholinesterase (AChE)-selective inhibitors, donepezil and galantamine, and the dual AChE and butyrylcholinesterase (BuChE) inhibitor, rivastigmine. Donepezil 162-171 butyrylcholinesterase Homo sapiens 28-31 12641367-4 2003 There were statistically significant differences between the 2 groups (MED versus GERO, respectively) at follow-up in terms of (1) institutionalization (30.0% versus 4.6%, P < .05), (2) CDR (2.3 versus 1.5, P < .005), and (3) prescription of donepezil at follow-up (45.5% versus 76.5%, P = .05). Donepezil 242-251 collagen type IX alpha 3 chain Homo sapiens 71-74 12716251-1 2003 BACKGROUND: In clinical trials, sleep problems have been identified as side effects of donepezil, an acetylcholinesterase (AChE)-inhibiting medication for the treatment of Alzheimer"s disease (AD). Donepezil 87-96 acetylcholinesterase (Cartwright blood group) Homo sapiens 101-121 12716251-1 2003 BACKGROUND: In clinical trials, sleep problems have been identified as side effects of donepezil, an acetylcholinesterase (AChE)-inhibiting medication for the treatment of Alzheimer"s disease (AD). Donepezil 87-96 acetylcholinesterase (Cartwright blood group) Homo sapiens 123-127 12618916-3 2003 OBJECTIVE: We investigated the extent to which the cholinesterase inhibitor donepezil reversed the attentional performance deficit in nucleus basalis magnocellularis (NBM) lesioned rats. Donepezil 76-85 butyrylcholinesterase Rattus norvegicus 51-65 12641372-0 2003 Long-term effects of donepezil on P300 auditory event-related potentials in patients with Alzheimer"s disease. Donepezil 21-30 E1A binding protein p300 Homo sapiens 34-38 12604096-2 2003 The long-acting AChE inhibitor donepezil (Aricept) is used to improve memory and other aspects of cognition in AD patients. Donepezil 31-40 acetylcholinesterase (Cartwright blood group) Homo sapiens 16-20 12604096-2 2003 The long-acting AChE inhibitor donepezil (Aricept) is used to improve memory and other aspects of cognition in AD patients. Donepezil 42-49 acetylcholinesterase (Cartwright blood group) Homo sapiens 16-20 12616671-2 2003 Risperidone and donepezil are both metabolized through cytochrome P450 2D6 and 3A4, raising the possibility of drug interactions with combination therapy. Donepezil 16-25 cytochrome P450 2D6 Homo sapiens 55-74 12641372-3 2003 Reduction of P300 latency associated with a parallel improvement of ADAS-J cog scores was observed after administration of 5 mg/day of DPZ in patients with AD. Donepezil 135-138 E1A binding protein p300 Homo sapiens 13-17 15352644-4 2003 Preliminary studies with donepezil, a centrally acting acetylcholinesterase (AChE) inhibitor approved for use in Alzheimer"s disease, have suggested at least short-term benefit in treating opiate-related sedation. Donepezil 25-34 acetylcholinesterase (Cartwright blood group) Homo sapiens 55-75 12641372-3 2003 Reduction of P300 latency associated with a parallel improvement of ADAS-J cog scores was observed after administration of 5 mg/day of DPZ in patients with AD. Donepezil 135-138 alkylglycerone phosphate synthase Homo sapiens 68-72 15352644-4 2003 Preliminary studies with donepezil, a centrally acting acetylcholinesterase (AChE) inhibitor approved for use in Alzheimer"s disease, have suggested at least short-term benefit in treating opiate-related sedation. Donepezil 25-34 acetylcholinesterase (Cartwright blood group) Homo sapiens 77-81 12641372-4 2003 P300 latency gives very useful information on the progression of AD, especially in the longitudinal follow-up of patients with AD during treatment with DPZ acting on cholinergic pathways. Donepezil 152-155 E1A binding protein p300 Homo sapiens 0-4 12589378-10 2003 the AChE inhibitors tacrine and donepezil differ in their ability to modify muscarinic-receptor-mediated function in vivo. Donepezil 32-41 acetylcholinesterase Rattus norvegicus 4-8 12712872-1 2003 A 75-years-old man with Alzheimer"s disease, treated with the cholinesterase inhibitor donepezil for 14 months, was scheduled for left colectomy under general anesthesia. Donepezil 87-96 butyrylcholinesterase Homo sapiens 62-76 12712872-4 2003 Such an effect, which has been described for cholinesterase inhibitors like neostigmine and donepezil, would explain the prolonged effect of succinylcholine. Donepezil 92-101 butyrylcholinesterase Homo sapiens 45-59 14535624-3 2003 The most selective AChE inhibitors, in decreasing sequence, were in order: TAK-147, donepezil and galantamine. Donepezil 84-93 acetylcholinesterase (Cartwright blood group) Homo sapiens 19-23 12494428-4 2003 To our knowledge, this is the first prospective study to evaluate systematically the effects of donepezil, a cholinesterase inhibitor, on specific language domains in DS. Donepezil 96-105 butyrylcholinesterase Homo sapiens 109-123 12567159-2 2003 Donepezil, a cholinesterase inhibitor, may be beneficial for the management of symptoms of Alzheimer"s disease, a disease in which cholinergic pathways in the cerebral cortex and basal forebrain are well known to be compromised. Donepezil 0-9 butyrylcholinesterase Homo sapiens 13-27 14687441-6 2003 A number of open-label studies, where patients were switched from donepezil to rivastigmine, have indicated that approximately 50% of patients experiencing a lack/loss of efficacy with donepezil (a selective acetylcholinesterase [AChE] inhibitor) respond to subsequent treatment with rivastigmine (a dual AChE and butyrylcholinesterase inhibitor). Donepezil 185-194 acetylcholinesterase (Cartwright blood group) Homo sapiens 208-228 14533945-5 2003 The four cholinesterase inhibitors (tacrine, donepezil, rivastigmine and galantamine) that are currently available have different pharmacological properties that expose patients to the risk of several types of drug interactions of nonequivalent clinical relevance. Donepezil 45-54 butyrylcholinesterase Homo sapiens 9-23 14687441-6 2003 A number of open-label studies, where patients were switched from donepezil to rivastigmine, have indicated that approximately 50% of patients experiencing a lack/loss of efficacy with donepezil (a selective acetylcholinesterase [AChE] inhibitor) respond to subsequent treatment with rivastigmine (a dual AChE and butyrylcholinesterase inhibitor). Donepezil 185-194 acetylcholinesterase (Cartwright blood group) Homo sapiens 230-234 12626850-2 2003 The cholinesterase inhibitor donepezil potentially affects parasympathetic activity. Donepezil 29-38 butyrylcholinesterase Homo sapiens 4-18 12688400-0 2003 Acetylcholinesterase inhibitor (donepezil hydrochloride) reduces heart rate variability. Donepezil 32-55 acetylcholinesterase (Cartwright blood group) Homo sapiens 0-20 12841930-3 2003 We performed an open study to evaluate the effect of ALC (2 g/day orally for 3 months) in association with donepezil or rivastigmine in 23 patients with mild AD who had not responded to treatment with acetylcholinesterase inhibitors (AChE-I). Donepezil 107-116 allantoicase Homo sapiens 53-56 16191240-2 2003 OBJECTIVE: To examine the population characteristics in patients with VaD enrolled in two randomized, double-blind, placebo-controlled, 24-week clinical trials of the efficacy and tolerability of the acetylcholinesterase inhibitor donepezil. Donepezil 231-240 acetylcholinesterase (Cartwright blood group) Homo sapiens 200-220 12934969-2 2003 In short- and long-term studies, the 3 cholinesterase inhibitors most commonly used, donepezil, rivastigmine, and galantamine, have demonstrated efficacy in improving not only cognition but also function and behavior in patients suffering from mild to severe cases of Alzheimer"s disease and other forms of dementia. Donepezil 85-94 butyrylcholinesterase Homo sapiens 39-53 14501021-8 2003 However, acetylcholinesterase inhibitors, such as donepezil (Aricept), which potentiate cholinergic neurotransmission, do have a therapeutic role in the management of AD and so the M1 receptor remains a viable therapeutic target. Donepezil 50-59 acetylcholinesterase (Cartwright blood group) Homo sapiens 9-29 14501021-8 2003 However, acetylcholinesterase inhibitors, such as donepezil (Aricept), which potentiate cholinergic neurotransmission, do have a therapeutic role in the management of AD and so the M1 receptor remains a viable therapeutic target. Donepezil 61-68 acetylcholinesterase (Cartwright blood group) Homo sapiens 9-29 12688400-1 2003 An acetylcholinesterase inhibitor (donepezil hydrochloride) has recently been used for the treatment of senile dementia of Alzheimer type. Donepezil 35-58 acetylcholinesterase (Cartwright blood group) Homo sapiens 3-23 12376170-0 2002 Chromaproline and Chromaperidine, nicotine agonists, and Donepezil, cholinesterase inhibitor, enhance performance of memory tasks in ovariectomized rats. Donepezil 57-66 butyrylcholinesterase Rattus norvegicus 68-82 12686754-1 2003 Donepezil, an acetylcholinesterase (AChE) inhibitor, has not been evaluated for its binding characteristics using a radioactive tracer, although its inhibitory action on AChE has been studied. Donepezil 0-9 acetylcholinesterase Rattus norvegicus 14-34 12686754-1 2003 Donepezil, an acetylcholinesterase (AChE) inhibitor, has not been evaluated for its binding characteristics using a radioactive tracer, although its inhibitory action on AChE has been studied. Donepezil 0-9 acetylcholinesterase Rattus norvegicus 36-40 12686754-2 2003 The aim of this research is to examine whether AChE can be visualized in vivo and in vitro with [(11)C]donepezil. Donepezil 103-112 acetylcholinesterase Rattus norvegicus 47-51 12445575-1 2002 Five inhibitors of acetylcholinesterase, huperzine A, donepezil, tacrine, rivastigmine and physostigmine, were compared with regard to their effects on different molecular forms of acetylcholinesterase in cerebral cortex, hippocampus, and striatum from the rat brain. Donepezil 54-63 acetylcholinesterase Rattus norvegicus 181-201 12417358-2 2002 These patients may therefore benefit from treatment with cholinesterase (ChE) inhibitors such as donepezil. Donepezil 97-106 butyrylcholinesterase Homo sapiens 57-71 12417358-2 2002 These patients may therefore benefit from treatment with cholinesterase (ChE) inhibitors such as donepezil. Donepezil 97-106 butyrylcholinesterase Homo sapiens 73-76 12480791-2 2002 Donepezil is a cholinesterase inhibitor used for the treatment of Alzheimer"s disease. Donepezil 0-9 butyrylcholinesterase Homo sapiens 15-29 12445575-3 2002 Donepezil showed pronounced selectivity for G1 acetylcholinesterase in striatum and hippocampus, but not in cortex. Donepezil 0-9 acetylcholinesterase Rattus norvegicus 47-67 12445575-5 2002 In cortex, the most potent inhibitors of G4 acetylcholinesterase were huperzine A (K(i) 7 x 10(-9) M) and donepezil (K(i) 4 x 10(-9) M). Donepezil 106-115 acetylcholinesterase Rattus norvegicus 44-64 12445575-6 2002 The potent inhibitors of cortical G1 acetylcholinesterase were donepezil (K(i) 3.5 x 10(-9) M) and tacrine (K(i) 2.3 x 10(-8) M). Donepezil 63-72 acetylcholinesterase Rattus norvegicus 37-57 12445575-7 2002 In hippocampus, huperzine A and physostigmine were the most potent inhibitors of G4 acetylcholinesterase, while donepezil and tacrine were most potent against G1 acetylcholinesterase. Donepezil 112-121 acetylcholinesterase Rattus norvegicus 162-182 12445575-8 2002 In striatum, huperzine A and donepezil were the most potent against G4 acetylcholinesterase, while again donepezil was the most potent against G1. Donepezil 29-38 acetylcholinesterase Rattus norvegicus 71-91 12436385-4 2002 There is evidence to show that the use of cholinesterase (ChE) inhibitors, including rivastigmine, donepezil and galanthamine, to enhance the survival of cholinergic neurotransmission is beneficial in the treatment of these symptoms. Donepezil 99-108 butyrylcholinesterase Homo sapiens 42-56 12410907-1 2002 OBJECTIVES: To evaluate the accuracy of artificial neural networks compared with discriminant analysis in classifying positive and negative response to the cholinesterase inhibitor donepezil in a group of Alzheimer"s disease (AD) patients. Donepezil 181-190 butyrylcholinesterase Homo sapiens 156-170 12436385-4 2002 There is evidence to show that the use of cholinesterase (ChE) inhibitors, including rivastigmine, donepezil and galanthamine, to enhance the survival of cholinergic neurotransmission is beneficial in the treatment of these symptoms. Donepezil 99-108 butyrylcholinesterase Homo sapiens 58-61 12450245-4 2002 More recent investigations have assessed acetylcholinesterase (AChE) and cholinesterase (ChE) inhibitors such as donepezil, rivastigmine and galantamine. Donepezil 113-122 acetylcholinesterase (Cartwright blood group) Homo sapiens 41-61 12151908-2 2002 We tested the hypothesis that new cholinesterase inhibitors like Donepezil (DPZ) may have an effect on the often abnormal P300 of patients with Alzheimer"s Disease (AD), and therefore, that P300 recordings might simplify the evaluation of responses to cholinesterase inhibitor in patients with mild and moderate-severe AD. Donepezil 65-74 butyrylcholinesterase Homo sapiens 34-48 12548360-3 2002 AChE activity in CSF was significantly increased after treatment with donepezil and galantamine; the opposite was observed in the rivastigmine-treated group. Donepezil 70-79 acetylcholinesterase (Cartwright blood group) Homo sapiens 0-4 12139367-3 2002 These events have been associated more with the dual acetylcholinesterase/butyrylcholinesterase (AChE/BuChE) inhibitor rivastigmine than with the AChE-selective inhibitors donepezil and galantamine, probably due to rivastigmine"s higher potency. Donepezil 172-181 acetylcholinesterase (Cartwright blood group) Homo sapiens 146-150 12139367-10 2002 Furthermore, rivastigmine preferentially inhibits the G1 isoform of cholinesterase, predominantly located in the cortex, hippocampus and in neuritic plaques, while donepezil and galantamine are not selective for any cholinesterase isoforms and have wide cholinergic activity both centrally and peripherally The cholinergic activity of rivastigmine, in contrast to donepezil and galantamine, is apparently more targeted at clinically relevant brain sites. Donepezil 364-373 butyrylcholinesterase Homo sapiens 68-82 12454562-1 2002 Donepezil and rivastigmine are acetylcholinesterase (AChE) inhibitors used to improve cholinergic neurotransmission and cognitive function in Alzheimer"s disease (AD). Donepezil 0-9 acetylcholinesterase (Cartwright blood group) Homo sapiens 53-57 12454562-6 2002 Treatment with donepezil reduced the AChE activity (k3 values) in the AD brain by 39% in the frontal (p < 0.001, Bonferroni corrected), 29% in the temporal (p = 0.02, corrected) and 28% in the parietal cortex (p = 0.05, corrected). Donepezil 15-24 acetylcholinesterase (Cartwright blood group) Homo sapiens 37-41 12454562-11 2002 Our results indicate that the pooled effects of donepezil and rivastigmine on brain AChE are greater in the frontal cortex compared to the temporal cortex in AD. Donepezil 48-57 acetylcholinesterase (Cartwright blood group) Homo sapiens 84-88 12187372-1 2002 Several studies have reported the efficacy of donepezil (a cholinesterase inhibitor) in patients with Alzheimer"s Disease, not only for memory disturbances but also for psychotic and behavioral disturbances. Donepezil 46-55 butyrylcholinesterase Homo sapiens 59-73 12105320-1 2002 We report a randomized, double-blind, parallel group, placebo-controlled study to test the effects of the acetylcholinesterase inhibitor, donepezil (5 mg/d for 30 days), on aircraft pilot performance in 18 licensed pilots with mean age of 52 years. Donepezil 138-147 acetylcholinesterase (Cartwright blood group) Homo sapiens 106-126 12147570-2 2002 Informal, open trial of the cholinesterase inhibitor donepezil resulted in uncertain benefit. Donepezil 53-62 butyrylcholinesterase Homo sapiens 28-42 12166537-0 2002 Cholinesterase inhibitors in Alzheimer"s disease: donepezil or rivastigmine? Donepezil 50-59 butyrylcholinesterase Homo sapiens 0-14 12111444-2 2002 Eighteen h after the last administration, cholinesterase inhibition was 85, 52 and 39% after metrifonate, rivastigmine and donepezil, respectively, and was accompanied by 988, 590 and 75% increase in cortical acetylcholine level. Donepezil 123-132 butyrylcholinesterase Rattus norvegicus 42-56 12142731-1 2002 The objective was to evaluate the effects of the apolipoprotein E (ApoE) genotype and gender on the response to donepezil treatment in Alzheimer"s disease. Donepezil 112-121 apolipoprotein E Homo sapiens 49-65 12142731-1 2002 The objective was to evaluate the effects of the apolipoprotein E (ApoE) genotype and gender on the response to donepezil treatment in Alzheimer"s disease. Donepezil 112-121 apolipoprotein E Homo sapiens 67-71 12117079-9 2002 In the RCTs of donepezil, the mean decrease in scores on the Alzheimer"s Disease Assessment Scale-cognitive subscale (ADAS-cog) was greater with active treatment than with placebo (lower scores indicate less cognitive deterioration). Donepezil 15-24 alkylglycerone phosphate synthase Homo sapiens 118-122 12081663-5 2002 Thirdly, the effect of the acetylcholinesterase inhibitor, donepezil (Aricept(R), E2020), on the resulting cognitive impairment was studied. Donepezil 59-68 acetylcholinesterase Rattus norvegicus 27-47 12151908-2 2002 We tested the hypothesis that new cholinesterase inhibitors like Donepezil (DPZ) may have an effect on the often abnormal P300 of patients with Alzheimer"s Disease (AD), and therefore, that P300 recordings might simplify the evaluation of responses to cholinesterase inhibitor in patients with mild and moderate-severe AD. Donepezil 65-74 butyrylcholinesterase Homo sapiens 252-266 12151908-2 2002 We tested the hypothesis that new cholinesterase inhibitors like Donepezil (DPZ) may have an effect on the often abnormal P300 of patients with Alzheimer"s Disease (AD), and therefore, that P300 recordings might simplify the evaluation of responses to cholinesterase inhibitor in patients with mild and moderate-severe AD. Donepezil 76-79 butyrylcholinesterase Homo sapiens 34-48 12151908-2 2002 We tested the hypothesis that new cholinesterase inhibitors like Donepezil (DPZ) may have an effect on the often abnormal P300 of patients with Alzheimer"s Disease (AD), and therefore, that P300 recordings might simplify the evaluation of responses to cholinesterase inhibitor in patients with mild and moderate-severe AD. Donepezil 76-79 butyrylcholinesterase Homo sapiens 252-266 12134305-6 2002 Up to now, although with limited success, this improvement has been achieved only with the reversible inhibitors of acetylcholinesterase tacrine, rivastigmine and donepezil, available in the clinic since a few years. Donepezil 163-172 acetylcholinesterase (Cartwright blood group) Homo sapiens 116-136 12023410-1 2002 OBJECTIVE: To study the safety and efficacy of the cholinesterase inhibitor donepezil in patients with Parkinson"s disease (PD) and cognitive impairment. Donepezil 76-85 butyrylcholinesterase Homo sapiens 51-65 11852291-0 2002 Therapeutic effects of an acetylcholinesterase inhibitor (donepezil) on memory in Wernicke-Korsakoff"s disease. Donepezil 58-67 acetylcholinesterase (Cartwright blood group) Homo sapiens 26-46 12083745-0 2002 Research and development of donepezil hydrochloride, a new type of acetylcholinesterase inhibitor. Donepezil 28-51 acetylcholinesterase (Cartwright blood group) Homo sapiens 67-87 12083745-8 2002 Donepezil showed several positive characteristics including the following: 1) It has a novel structure compared to other conventional ChE inhibitors; 2) It shows strong anti-AChE activity and has long lasting efficacy; 3) The inhibitory characteristic of donepezil shows that it is highly selective for AChE as compared to butyrylcholinesterase (BuChE) and showed reversibility; 4) The results of clinical studies on donepezil show a very high significant difference on ADAS cog and CIBIC plus scores of AD patients. Donepezil 0-9 butyrylcholinesterase Homo sapiens 134-137 12083745-8 2002 Donepezil showed several positive characteristics including the following: 1) It has a novel structure compared to other conventional ChE inhibitors; 2) It shows strong anti-AChE activity and has long lasting efficacy; 3) The inhibitory characteristic of donepezil shows that it is highly selective for AChE as compared to butyrylcholinesterase (BuChE) and showed reversibility; 4) The results of clinical studies on donepezil show a very high significant difference on ADAS cog and CIBIC plus scores of AD patients. Donepezil 0-9 acetylcholinesterase (Cartwright blood group) Homo sapiens 174-178 12083745-8 2002 Donepezil showed several positive characteristics including the following: 1) It has a novel structure compared to other conventional ChE inhibitors; 2) It shows strong anti-AChE activity and has long lasting efficacy; 3) The inhibitory characteristic of donepezil shows that it is highly selective for AChE as compared to butyrylcholinesterase (BuChE) and showed reversibility; 4) The results of clinical studies on donepezil show a very high significant difference on ADAS cog and CIBIC plus scores of AD patients. Donepezil 0-9 acetylcholinesterase (Cartwright blood group) Homo sapiens 303-307 12083745-8 2002 Donepezil showed several positive characteristics including the following: 1) It has a novel structure compared to other conventional ChE inhibitors; 2) It shows strong anti-AChE activity and has long lasting efficacy; 3) The inhibitory characteristic of donepezil shows that it is highly selective for AChE as compared to butyrylcholinesterase (BuChE) and showed reversibility; 4) The results of clinical studies on donepezil show a very high significant difference on ADAS cog and CIBIC plus scores of AD patients. Donepezil 0-9 alkylglycerone phosphate synthase Homo sapiens 470-474 12083745-8 2002 Donepezil showed several positive characteristics including the following: 1) It has a novel structure compared to other conventional ChE inhibitors; 2) It shows strong anti-AChE activity and has long lasting efficacy; 3) The inhibitory characteristic of donepezil shows that it is highly selective for AChE as compared to butyrylcholinesterase (BuChE) and showed reversibility; 4) The results of clinical studies on donepezil show a very high significant difference on ADAS cog and CIBIC plus scores of AD patients. Donepezil 255-264 butyrylcholinesterase Homo sapiens 134-137 12083745-8 2002 Donepezil showed several positive characteristics including the following: 1) It has a novel structure compared to other conventional ChE inhibitors; 2) It shows strong anti-AChE activity and has long lasting efficacy; 3) The inhibitory characteristic of donepezil shows that it is highly selective for AChE as compared to butyrylcholinesterase (BuChE) and showed reversibility; 4) The results of clinical studies on donepezil show a very high significant difference on ADAS cog and CIBIC plus scores of AD patients. Donepezil 255-264 acetylcholinesterase (Cartwright blood group) Homo sapiens 174-178 12083745-8 2002 Donepezil showed several positive characteristics including the following: 1) It has a novel structure compared to other conventional ChE inhibitors; 2) It shows strong anti-AChE activity and has long lasting efficacy; 3) The inhibitory characteristic of donepezil shows that it is highly selective for AChE as compared to butyrylcholinesterase (BuChE) and showed reversibility; 4) The results of clinical studies on donepezil show a very high significant difference on ADAS cog and CIBIC plus scores of AD patients. Donepezil 255-264 acetylcholinesterase (Cartwright blood group) Homo sapiens 303-307 12083745-8 2002 Donepezil showed several positive characteristics including the following: 1) It has a novel structure compared to other conventional ChE inhibitors; 2) It shows strong anti-AChE activity and has long lasting efficacy; 3) The inhibitory characteristic of donepezil shows that it is highly selective for AChE as compared to butyrylcholinesterase (BuChE) and showed reversibility; 4) The results of clinical studies on donepezil show a very high significant difference on ADAS cog and CIBIC plus scores of AD patients. Donepezil 255-264 alkylglycerone phosphate synthase Homo sapiens 470-474 11982550-4 2002 A cholinesterase inhibitor, donepezil, was introduced. Donepezil 28-37 butyrylcholinesterase Homo sapiens 2-16 11888054-0 2002 Determination of donepezil, an acetylcholinesterase inhibitor, in human plasma by high-performance liquid chromatography with ultraviolet absorbance detection. Donepezil 17-26 acetylcholinesterase (Cartwright blood group) Homo sapiens 31-51 12137632-36 2002 This magnitude for the cognitive effect is similar to that associated with other cholinesterase inhibitors including donepezil, rivastigmine, and tacrine. Donepezil 117-126 butyrylcholinesterase Homo sapiens 81-95 12094822-2 2002 Donepezil is a specific, reversible inhibitor of AChE, while rivastigmine is a slowly reversible (pseudoirreversible) dual cholinesterase (ChE) inhibitor, with brain-regional specificity for the cerebral cortex and hippocampus. Donepezil 0-9 acetylcholinesterase (Cartwright blood group) Homo sapiens 49-53 12094822-2 2002 Donepezil is a specific, reversible inhibitor of AChE, while rivastigmine is a slowly reversible (pseudoirreversible) dual cholinesterase (ChE) inhibitor, with brain-regional specificity for the cerebral cortex and hippocampus. Donepezil 0-9 butyrylcholinesterase Homo sapiens 50-53 12240787-6 2002 Rivastigmine was well tolerated by our patients when the dose was escalated slowly, including one patient who had previously experienced severe side-effects with the AChE-selective inhibitor donepezil. Donepezil 191-200 acetylcholinesterase (Cartwright blood group) Homo sapiens 166-170 11824442-2 2001 (1) The reference symptomatic treatment for mild to moderate Alzheimer"s disease is a cholinesterase inhibitor such as donepezil, but efficacy is only moderate and only about 10% of those patients treated actually benefit. Donepezil 119-128 butyrylcholinesterase Homo sapiens 86-100 11728425-7 2001 The effects observed with SCH 57790 in behavioral studies were qualitatively similar to the effects produced by the clinically used cholinesterase inhibitor donepezil, suggesting that blockade of muscarinic M(2) receptors is a viable approach to enhancing cognitive performance. Donepezil 157-166 butyrylcholinesterase Rattus norvegicus 132-146 11689088-1 2001 The design, synthesis, and rapid evaluation of a new class of acetylcholinesterase (AChE) inhibitors related to donepezil are reported. Donepezil 112-121 acetylcholinesterase (Cartwright blood group) Homo sapiens 62-82 11689088-1 2001 The design, synthesis, and rapid evaluation of a new class of acetylcholinesterase (AChE) inhibitors related to donepezil are reported. Donepezil 112-121 acetylcholinesterase (Cartwright blood group) Homo sapiens 84-88 11581527-5 2001 Centrally acting cholinesterase inhibitors, such as rivastigmine, donepezil, and galantamine partially reverse decreased cortical cholinergic activity and may improve cognition and neuropsychiatric symptoms in DLB. Donepezil 66-75 butyrylcholinesterase Homo sapiens 17-31 12007670-0 2002 ApoE genotype influences the biological effect of donepezil on APP metabolism in Alzheimer disease: evidence from a peripheral model. Donepezil 50-59 apolipoprotein E Homo sapiens 0-4 12007670-8 2002 The present study provides evidence that donepezil influences APP metabolism in platelets, and suggests that ApoE genotype might be an important modulating factor for drug responsiveness in AD. Donepezil 41-50 apolipoprotein E Homo sapiens 109-113 12162759-5 2002 Cholinesterase inhibitors are rapidly absorbed through the gastrointestinal tract, with time to peak concentration usually less than 2 hours; donepezil has the longest absorption time of 3 to 5 hours. Donepezil 142-151 butyrylcholinesterase Homo sapiens 0-14 12162759-7 2002 Tacrine is metabolised by hepatic cytochrome P450 (CYP) 1A2, and donepezil and galantamine are metabolised by CYP3A4 and CYP2D6. Donepezil 65-74 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 110-116 12162759-7 2002 Tacrine is metabolised by hepatic cytochrome P450 (CYP) 1A2, and donepezil and galantamine are metabolised by CYP3A4 and CYP2D6. Donepezil 65-74 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 121-127 12162759-10 2002 Tacrine and rivastigmine inhibit both enzymes, whereas donepezil and galantamine specifically inhibit AChE. Donepezil 55-64 acetylcholinesterase (Cartwright blood group) Homo sapiens 102-106 12636182-1 2002 This review provides an overview of the three most widely used cholinesterase (ChE) inhibitors: donepezil, rivastigmine, and galantamine. Donepezil 96-105 butyrylcholinesterase Homo sapiens 63-77 12636182-1 2002 This review provides an overview of the three most widely used cholinesterase (ChE) inhibitors: donepezil, rivastigmine, and galantamine. Donepezil 96-105 butyrylcholinesterase Homo sapiens 79-82 11852291-4 2002 The objective of this study was to assess the effects of a cholinesterase inhibitor, donepezil, on memory, attention, and executive functions in patients with nonalcoholic WKD. Donepezil 85-94 butyrylcholinesterase Homo sapiens 59-73 11589922-0 2001 Cerebrospinal fluid acetylcholinesterase activity after long-term treatment with donepezil and rivastigmina. Donepezil 81-90 acetylcholinesterase (Cartwright blood group) Homo sapiens 20-40 11589922-2 2001 This study was designed to assess the effects of 6-12 month treatment with AChEIs donepezil and rivastigmine on cerebrospinal fluid (CSF) AChE and butyrylcholinesterase (BuChE) activity in AD patients. Donepezil 82-91 acetylcholinesterase (Cartwright blood group) Homo sapiens 75-79 11589922-4 2001 In AD patients treated with donepezil a significant increase of CFS AChE activity was observed, whereas treatment with rivastigmine induced a significant decrease of AChE activity. Donepezil 28-37 acetylcholinesterase (Cartwright blood group) Homo sapiens 68-72 11459683-3 2001 Patients were studied before and during treatment with the cholinesterase inhibitor donepezil. Donepezil 84-93 butyrylcholinesterase Homo sapiens 59-73 11782241-2 2001 OBJECTIVE: To assess the clinical and cognitive effects of adding donepezil, a reversible acetylcholinesterase inhibitor, to the risperidone treatment of a high functioning stable out-patient with schizophrenia. Donepezil 66-75 acetylcholinesterase (Cartwright blood group) Homo sapiens 90-110 19811047-3 2001 The three new acetylcholinesterase inhibitors licensed to treat Alzheimer"s disease (donepezil, rivastigmine and galantamine) have provided clinicians with a major impetus to their desire to diagnose and treat this lethal disease. Donepezil 85-94 acetylcholinesterase (Cartwright blood group) Homo sapiens 14-34 11502918-8 2001 CONCLUSION: As the first 1-year, multinational, double-blinded, placebo-controlled study of a cholinesterase inhibitor in AD, these data support donepezil as a well tolerated and effective long-term treatment for patients with AD, with benefits over placebo on global assessment, cognition, and ADL. Donepezil 145-154 butyrylcholinesterase Homo sapiens 94-108 11669506-8 2001 Conventional AChE inhibitors (rivastigmine and donepezil) have maintained ADAS-cog baseline scores for up to 40 weeks in open extension studies, and Mini-Mental State Examination (MMSE) scores for up to 52 weeks in a placebo-controlled study. Donepezil 47-56 acetylcholinesterase (Cartwright blood group) Homo sapiens 13-17 11669506-8 2001 Conventional AChE inhibitors (rivastigmine and donepezil) have maintained ADAS-cog baseline scores for up to 40 weeks in open extension studies, and Mini-Mental State Examination (MMSE) scores for up to 52 weeks in a placebo-controlled study. Donepezil 47-56 alkylglycerone phosphate synthase Homo sapiens 74-78 11585854-1 2001 UNLABELLED: The aim of this SPECT study was to investigate the effects of donepezil on regional cerebral blood flow (rCBF) in patients with mild to moderate Alzheimer"s disease (AD) using statistical parametric mapping. Donepezil 74-83 CCAAT/enhancer binding protein zeta Rattus norvegicus 117-121 11585854-5 2001 RESULTS: In the follow-up study, the adjusted rCBF was significantly preserved in the right and left anterior cingulate gyri, right middle temporal gyrus, right inferior parietal lobules, and prefrontal cortex of donepezil-treated AD patients, compared with placebo-treated AD patients. Donepezil 213-222 CCAAT/enhancer binding protein zeta Rattus norvegicus 46-50 11585854-6 2001 CONCLUSION: Treatment with donepezil for 1 y appears to reduce the decline in rCBF, suggesting preservation of functional brain activity. Donepezil 27-36 CCAAT/enhancer binding protein zeta Rattus norvegicus 78-82 11488374-0 2001 Pisa syndrome due to a cholinesterase inhibitor (donepezil): a case report. Donepezil 49-58 butyrylcholinesterase Homo sapiens 23-37 12404557-0 2001 Cholinergic modulation of cognitive function in healthy subjects: acute effects of donepezil, a cholinesterase inhibitor. Donepezil 83-92 butyrylcholinesterase Homo sapiens 96-110 11150706-0 2000 Pharmacological evaluation of [11C]donepezil as a tracer for visualization of acetylcholinesterase by PET. Donepezil 35-44 thyroid stimulating hormone receptor Mus musculus 102-105 11475420-4 2001 Similar measurements were also performed in another group of patients with AD who were treated with a cholinesterase inhibitor (Donepezil, Aricept). Donepezil 128-137 butyrylcholinesterase Homo sapiens 102-116 11394735-10 2001 After performing our modelling study the X-ray structure of AChE complexed with donepezil, an inhibitor structurally related to the developed aminopyirdazines, has been made available. Donepezil 80-89 acetylcholinesterase (Cartwright blood group) Homo sapiens 60-64 11226635-3 2001 However, CSF-AChE was significantly increased after treatment of AD patients with AChE inhibitors (donepezil and galantamine). Donepezil 99-108 acetylcholinesterase (Cartwright blood group) Homo sapiens 13-17 11290880-2 2001 We tested the hypothesis that the new cholinesterase inhibitors donepezil (DPZ) and rivastigmine (Riv) may have an effect on the frequently abnormal P300 component in patients with Alzheimer disease (AD), thereby allowing a significant evaluation of cholinesterase inhibitors. Donepezil 64-73 butyrylcholinesterase Homo sapiens 38-52 11290880-2 2001 We tested the hypothesis that the new cholinesterase inhibitors donepezil (DPZ) and rivastigmine (Riv) may have an effect on the frequently abnormal P300 component in patients with Alzheimer disease (AD), thereby allowing a significant evaluation of cholinesterase inhibitors. Donepezil 64-73 butyrylcholinesterase Homo sapiens 250-264 11290880-2 2001 We tested the hypothesis that the new cholinesterase inhibitors donepezil (DPZ) and rivastigmine (Riv) may have an effect on the frequently abnormal P300 component in patients with Alzheimer disease (AD), thereby allowing a significant evaluation of cholinesterase inhibitors. Donepezil 75-78 butyrylcholinesterase Homo sapiens 38-52 11290880-2 2001 We tested the hypothesis that the new cholinesterase inhibitors donepezil (DPZ) and rivastigmine (Riv) may have an effect on the frequently abnormal P300 component in patients with Alzheimer disease (AD), thereby allowing a significant evaluation of cholinesterase inhibitors. Donepezil 75-78 butyrylcholinesterase Homo sapiens 250-264 11290880-8 2001 Correlations between ADAS-cog changes and P300 changes significantly separated patients treated with DPZ and Riv from those treated with vitamin E. Donepezil 101-104 alkylglycerone phosphate synthase Homo sapiens 21-25 11142177-2 2000 Current treatments such as the cholinesterase inhibitors donepezil and rivastigmine can slow the progression of cognitive and functional deficits in AD over the short term. Donepezil 57-66 butyrylcholinesterase Homo sapiens 31-45 11142178-7 2000 Emerging pharmacoeconomic data indicate potential savings in medical care costs associated with early treatment of AD and the potential cost effectiveness of cholinesterase inhibitors such as donepezil. Donepezil 192-201 butyrylcholinesterase Homo sapiens 158-172 11180473-3 2000 After treatment with donepezil, a cholinesterase inhibitor, ratings of behavioural symptoms improved. Donepezil 21-30 butyrylcholinesterase Homo sapiens 34-48 11441435-2 2001 OBJECTIVE: The present study aimed to examine the effects of globally increasing cholinergic function with the acetylcholinesterase inhibitor donepezil on inspection time. Donepezil 142-151 acetylcholinesterase (Cartwright blood group) Homo sapiens 111-131 11304753-6 2001 The cholinesterase inhibitor Aricept administered at doses of 50 and 250 microg/kg increased acetylcholine level in extracellular fluid of the frontal cortex and the binding of [(11)C](+)3-PPB with the lowest affinity to the receptors was displaced by the endogenous acetylcholine induced by cholinesterase inhibition, while [(11)C](+)3-MPB with the highest affinity was not significantly affected. Donepezil 29-36 butyrylcholinesterase Rattus norvegicus 4-18 11304753-6 2001 The cholinesterase inhibitor Aricept administered at doses of 50 and 250 microg/kg increased acetylcholine level in extracellular fluid of the frontal cortex and the binding of [(11)C](+)3-PPB with the lowest affinity to the receptors was displaced by the endogenous acetylcholine induced by cholinesterase inhibition, while [(11)C](+)3-MPB with the highest affinity was not significantly affected. Donepezil 29-36 butyrylcholinesterase Rattus norvegicus 292-306 11369163-1 2001 Donepezil, an oral acetylcholinesterase inhibitor approved for the treatment of Alzheimer"s disease, was given to 6 cancer pain patients having sedation related to the analgesic use of opioids. Donepezil 0-9 acetylcholinesterase (Cartwright blood group) Homo sapiens 19-39 11255446-1 2001 BACKGROUND: Donepezil hydrochloride is a selective acetylcholinesterase inhibitor approved for the symptomatic treatment of mild to moderately severe Alzheimer disease (AD). Donepezil 12-35 acetylcholinesterase (Cartwright blood group) Homo sapiens 51-71 11274994-12 2001 These results indicated that E2030 and donepezil exhibited the most marked preferential central cholinergic activity, relative to peripheral activity, among cholinesterase inhibitors tested. Donepezil 39-48 butyrylcholinesterase Rattus norvegicus 157-171 11171913-0 2001 Effect of donepezil on brain acetylcholinesterase activity in patients with AD measured by PET. Donepezil 10-19 acetylcholinesterase (Cartwright blood group) Homo sapiens 29-49 11171913-1 2001 Acetylcholinesterase (AChE) activities in the brain of three patients with AD were measured once before and once during donepezil treatment (5 mg/d in two patients, 3 mg/d in one patient) using PET and N-[11C]methylpiperidin-4-yl acetate. Donepezil 120-129 acetylcholinesterase (Cartwright blood group) Homo sapiens 0-20 11171913-2 2001 Donepezil reduced k(3) values, an index of AChE activity, in the cerebral cortex by 39 +/- 5%. Donepezil 0-9 acetylcholinesterase (Cartwright blood group) Homo sapiens 43-47 11227131-1 2001 OBJECTIVES: To evaluate the effect of 3 month therapy with donepezil, a centrally acting cholinesterase inhibitor, on cognitive performances, motor function and daily living activities in progressive supranuclear palsy (PSP). Donepezil 59-68 butyrylcholinesterase Homo sapiens 89-103 11226748-2 2001 The present study indicates that in the elderly, donepezil, an acetylcholinesterase inhibitor, also exerts a marked effect on REM sleep parameters--percentage of REM sleep and REM density were increased whereas REM latency was reduced. Donepezil 49-58 acetylcholinesterase (Cartwright blood group) Homo sapiens 63-83 11830754-3 2001 Donepezil is a piperidine-based, reversible acetylcholinesterase inhibitor, that is chemically unrelated to other cholinesterase inhibitors. Donepezil 0-9 acetylcholinesterase (Cartwright blood group) Homo sapiens 44-64 11830754-3 2001 Donepezil is a piperidine-based, reversible acetylcholinesterase inhibitor, that is chemically unrelated to other cholinesterase inhibitors. Donepezil 0-9 acetylcholinesterase (Cartwright blood group) Homo sapiens 50-64 11830754-5 2001 Donepezil is highly selective for acetylcholinesterase with a significantly lower affinity for butyrylcholinesterase, which is present predominantly in the periphery. Donepezil 0-9 acetylcholinesterase (Cartwright blood group) Homo sapiens 34-54 11078030-1 2000 Three new cholinesterase inhibitors, donepezil, rivastigmine, and galantamine, all inhibit the enzyme AChE. Donepezil 37-46 butyrylcholinesterase Homo sapiens 10-24 11078030-1 2000 Three new cholinesterase inhibitors, donepezil, rivastigmine, and galantamine, all inhibit the enzyme AChE. Donepezil 37-46 acetylcholinesterase (Cartwright blood group) Homo sapiens 102-106 11256231-4 2000 The order of inhibitory potency (IC50) towards AChE activity under optimal assay conditions for each ChE inhibitor was: physostigmine (0.67 nM) > rivastigmine (4.3 nM) > donepezil (6.7 nM) > TAK-147 (12 nM) > tacrine (77 nM) > ipidacrine (270 nM). Donepezil 170-179 acetylcholinesterase (Cartwright blood group) Homo sapiens 47-51 11256231-4 2000 The order of inhibitory potency (IC50) towards AChE activity under optimal assay conditions for each ChE inhibitor was: physostigmine (0.67 nM) > rivastigmine (4.3 nM) > donepezil (6.7 nM) > TAK-147 (12 nM) > tacrine (77 nM) > ipidacrine (270 nM). Donepezil 170-179 butyrylcholinesterase Homo sapiens 48-51 11256231-0 2000 Comparison of inhibitory activities of donepezil and other cholinesterase inhibitors on acetylcholinesterase and butyrylcholinesterase in vitro. Donepezil 39-48 acetylcholinesterase (Cartwright blood group) Homo sapiens 88-108 11256231-0 2000 Comparison of inhibitory activities of donepezil and other cholinesterase inhibitors on acetylcholinesterase and butyrylcholinesterase in vitro. Donepezil 39-48 butyrylcholinesterase Homo sapiens 113-134 11256231-1 2000 This study was designed to compare the in vitro inhibitory effects on acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) of donepezil and some other cholinesterase (ChE) inhibitors which have been developed for the treatment of Alzheimer"s disease. Donepezil 135-144 acetylcholinesterase (Cartwright blood group) Homo sapiens 70-90 11256231-1 2000 This study was designed to compare the in vitro inhibitory effects on acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) of donepezil and some other cholinesterase (ChE) inhibitors which have been developed for the treatment of Alzheimer"s disease. Donepezil 135-144 acetylcholinesterase (Cartwright blood group) Homo sapiens 92-96 11256231-1 2000 This study was designed to compare the in vitro inhibitory effects on acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) of donepezil and some other cholinesterase (ChE) inhibitors which have been developed for the treatment of Alzheimer"s disease. Donepezil 135-144 butyrylcholinesterase Homo sapiens 102-123 11256231-1 2000 This study was designed to compare the in vitro inhibitory effects on acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) of donepezil and some other cholinesterase (ChE) inhibitors which have been developed for the treatment of Alzheimer"s disease. Donepezil 135-144 butyrylcholinesterase Homo sapiens 125-130 11256231-1 2000 This study was designed to compare the in vitro inhibitory effects on acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) of donepezil and some other cholinesterase (ChE) inhibitors which have been developed for the treatment of Alzheimer"s disease. Donepezil 135-144 butyrylcholinesterase Homo sapiens 76-90 11256231-5 2000 The benzylpiperidine derivatives donepezil and TAK-147 showed high selectivity for AChE over BuChE. Donepezil 33-42 acetylcholinesterase (Cartwright blood group) Homo sapiens 83-87 11256231-1 2000 This study was designed to compare the in vitro inhibitory effects on acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) of donepezil and some other cholinesterase (ChE) inhibitors which have been developed for the treatment of Alzheimer"s disease. Donepezil 135-144 butyrylcholinesterase Homo sapiens 93-96 11256231-5 2000 The benzylpiperidine derivatives donepezil and TAK-147 showed high selectivity for AChE over BuChE. Donepezil 33-42 butyrylcholinesterase Homo sapiens 93-98 10996445-5 2000 The above-mentioned neuroprotective effects are also observed with tacrine (1 microM), donepezil (10 microM) and galanthamine (10 microM), suggesting that the neuroprotective effects of cholinesterase inhibitor might partly contribute to the clinical efficacy in AD treatment. Donepezil 87-96 butyrylcholinesterase Rattus norvegicus 186-200 10994012-1 2000 Three patients with REM behavior disorder whose nocturnal symptoms were markedly improved by treatment with the acetylcholinesterase inhibitor donepezil are reported. Donepezil 143-152 acetylcholinesterase (Cartwright blood group) Homo sapiens 112-132 10937606-1 2000 BACKGROUND: This open-label study examined the effects of the reversible cholinesterase inhibitor donepezil on emotional/behavioral symptoms in Alzheimer"s disease (AD) patients. Donepezil 98-107 butyrylcholinesterase Homo sapiens 73-87 10976649-0 2000 Limited donepezil inhibition of acetylcholinesterase measured with positron emission tomography in living Alzheimer cerebral cortex. Donepezil 8-17 acetylcholinesterase (Cartwright blood group) Homo sapiens 32-52 10976649-1 2000 Based on surrogate assays of peripheral red blood cells, reports state that widely prescribed doses of donepezil hydrochloride provide nearly complete inhibition of cerebral cortical acetylcholinesterase activity in the treatment of Alzheimer"s disease (AD). Donepezil 103-126 acetylcholinesterase (Cartwright blood group) Homo sapiens 183-203 11029868-3 2000 The cholinesterase inhibitors (tacrine, donepezil, and rivastigmine) are the only FDA-approved class of medications for AD. Donepezil 40-49 butyrylcholinesterase Homo sapiens 4-18 10984001-3 2000 This study examines the use of the cholinesterase inhibitor donepezil in the treatment of patients with a history of brain injury and subsequent cognitive impairment. Donepezil 60-69 butyrylcholinesterase Homo sapiens 35-49 10984725-5 2000 All patients were prescribed the AChE inhibitor donepezil (5 mg per day). Donepezil 48-57 acetylcholinesterase (Cartwright blood group) Homo sapiens 33-37 10960883-8 2000 In those patients who showed improvement and were maintained on donepezil, improvements were sustained for 18 months on the MMSE and NPI, 15 months on the NPI-D, and for 6 months on the ADAS-cog. Donepezil 64-73 alkylglycerone phosphate synthase Homo sapiens 186-190 11343620-3 2000 Nevertheless, symptomatic relief is a feasible treatment option for AD patients and is available currently in the form of cholinesterase inhibitors such as tacrine, donepezil, metrifonate and rivastigmine. Donepezil 165-174 butyrylcholinesterase Homo sapiens 122-136 11343620-4 2000 Donepezil is a second-generation, piperidine-class, selective and reversible acetylcholinesterase inhibitor. Donepezil 0-9 acetylcholinesterase (Cartwright blood group) Homo sapiens 77-97 10849891-0 2000 Donepezil, a centrally acting acetylcholinesterase inhibitor, alleviates learning deficits in hypocholinergic models in rats. Donepezil 0-9 acetylcholinesterase Rattus norvegicus 30-50 22033801-3 2000 Five such agents are reviewed: tacrine and donepezil, which act at the ionic subsite of acetylcholinesterase (AChE), and rivastigmine, galantamine, and metrifonate, which act at its catalytic esteratic subsite. Donepezil 43-52 acetylcholinesterase (Cartwright blood group) Homo sapiens 88-108 22033801-3 2000 Five such agents are reviewed: tacrine and donepezil, which act at the ionic subsite of acetylcholinesterase (AChE), and rivastigmine, galantamine, and metrifonate, which act at its catalytic esteratic subsite. Donepezil 43-52 acetylcholinesterase (Cartwright blood group) Homo sapiens 110-114 22034442-6 2000 Cholinesterase inhibitors, including donepezil, tacrine, rivastigmine, and galantamine are the recommended treatment of cognitive disturbance in patients with Alzheimer"s disease. Donepezil 37-46 butyrylcholinesterase Homo sapiens 0-14 10804078-3 2000 There were statistically significant differences between the two groups (MED vs. GERO, respectively) at follow-up in terms of: 1) hospitalization (39% vs. 15%; P